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I Methods and information sources
In the context of this report, ‘new benzodiazepines’ are 
defined as new psychoactive substances (NPS) that 
contain a benzodiazepine core, including structurally 
closely related compounds (e.g. thienodiazepines), and 
that are not controlled under the international drug control 
system. They also include three benzodiazepines – 
phenazepam, etizolam and flualprazolam – that 
were formerly classed as NPS but have recently been 
controlled under the international drug control system. 
Other common names for this category are ‘designer 
benzodiazepines’, ‘NPS benzodiazepines’ and, less 
frequently, ‘synthetic benzodiazepine analogues’.
English-language articles were selected from a search of 
the PubMed and Web of Science databases performed on 
18 June 2018 using the following search strings: (1) ‘(NPS 
OR “new psychoactive substance*”) AND benzodiazepine*’ 
and (2) ‘designer benzodiazepine*’. Additional articles 
were identified from a review of the references cited in 
retrieved publications (snowball technique). Searches 
of selected medical specialty society and international, 
national and local government agency websites were 
conducted to identify clinical guidelines, position 
statements and reports. Search strings were introduced 
into Google and Google Scholar and the first 100 hits were 
screened to find additional relevant content. Although the 
systematic searches were conducted in 2018, information 
from the scientific papers and reports published in 2019 
and 2020 was also included in this report. In particular, 
the most recent data on flualprazolam and etizolam were 
added. All the references in the European Database on 
New Drugs for substances listed in the benzodiazepine 
category were also included, except patents.
MEDLINE, PubMed, Google and internet platforms (e.g. 
Erowid, Bluelight, Eve and Rave) were searched for the 
terms ‘designer benzodiazepines’, ‘NPS benzodiazepines’, 
‘legal benzodiazepines’, ‘flubromazolam’, ‘flualprazolam’, 
‘fluclotizolam’, ‘diclazepam’, ‘clonazolam’, ‘clonitrazolam’, 
‘norfludiazepam’ and ‘bromazolam’, alone or in combination, 
in May 2019. In addition, colleagues within our scientific 
network were contacted to obtain further information.
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Statement on the United Kingdom
The United Kingdom left the European Union on 
1 February 2020. For the purpose of this report, the 
United Kingdom is not included in the term ‘Member 
States’.
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Information from the European Union Early Warning 
System on NPS (EWS), operated by the European 
Monitoring Centre for Drugs and Drug Addiction, has 
been included as relevant. The EWS is composed of 
a multiagency and multidisciplinary network, which 
includes the EMCDDA, 29 national early warning systems 
(27 EU Member States, Turkey, and Norway), Europol and 
its law enforcement networks, the European Medicines 
Agency (EMA), the European Commission, and other 
partners. Information from the United Nations system (the 
United Nations Office on Drugs and Crime and the World 
Health Organization), as well as from non-EU countries 
such as Canada, the United Kingdom and the United 
States, has also been included as relevant.
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I Executive summary
Benzodiazepines are one of the most important groups 
of medicines that are specifically used for sedation and 
to aid sleep. They are the most widely prescribed group 
of medicines in the world and are used to treat a range 
of conditions, including anxiety, insomnia, epilepsy and 
alcohol withdrawal. Benzodiazepines were introduced into 
clinical medicine in the early 1960s. They rapidly replaced 
barbiturates as sedative-hypnotics because they were 
safer and less likely to cause fatal central nervous system 
depression. Benzodiazepines act as central nervous 
system depressants by enhancing the actions of the 
neurotransmitter gamma-aminobutyric acid (GABA) on the 
benzodiazepine site of the GABA type A (GABA
A
) receptor. 
Their effects include anxiolytic and sedative effects, 
muscle relaxation and anticonvulsive activity.
Since the mid 2000s, new benzodiazepines, which are not 
controlled under the international drug control system, 
have been sold as ‘legal’ replacements for controlled 
benzodiazepines in Europe. A small number of these new 
benzodiazepines, such as phenazepam and etizolam, are 
authorised medicines in some countries; many others 
may be found in the scientific and patent literature, but 
have never been authorised as medicines, and some are 
novel compounds. In Europe, new benzodiazepines are 
monitored as new psychoactive substances (NPS) by the 
European Union Early Warning System. This system is 
operated by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) as part of a three-step legal 
framework allowing the EU to rapidly detect, assess, and 
respond to public health and social threats caused by such 
substances.
Over the past few years, there has been an increase in the 
number and availability of new benzodiazepines on the 
drug market in Europe and, increasingly, in Canada and the 
United States. As of 28 February 2021, the EMCDDA was 
monitoring 30 new benzodiazepines through the EU Early 
Warning System. Of these, more than 80 % were detected 
for the first time between 2014 and 2020. Despite this 
relatively large number, the new benzodiazepine market in 
Europe is currently dominated by a handful of substances, 
most notably etizolam and flualprazolam, although this 
may change, as both substances were placed under 
international control in November 2020. In 2019, 1 240 
seizures of new benzodiazepines were reported to the EU 
Early Warning System by the Member States, reflecting 
around 5 % of the total number of seizures of NPS.
Overall, these developments in the market give rise to 
concerns about both individual and public health for 
a number of reasons. The pharmacology and toxicology 
of new benzodiazepines is largely unknown, and the 
risks associated with their use may be higher than those 
associated with the use of authorised benzodiazepine 
medicines. In addition, the very nature of unregulated 
markets means that these risks may be amplified by the 
uncertain doses that are used. In some cases, users may 
not be aware that they are using these substances, and 
therefore might be at higher risk of severe poisoning, 
particularly if taken in combination with other central 
nervous system depressants, such as alcohol and 
opioids. Of particular concern is the growing use of 
new benzodiazepines to make falsified (fake) tablets of 
commonly prescribed benzodiazepine medicines, such 
as diazepam (Valium) and alprazolam (Xanax), and the 
involvement of criminal groups in producing such tablets. 
In some cases, the fake tablets are packaged in blister 
packs resembling legitimate products, which makes it 
more difficult for consumers to spot the fakes. Serious 
adverse events, such as severe poisonings, involving such 
fake medicines have been reported in Europe. Other risks 
might be related to the potential presence of adulterants, 
other substances or synthesis by-products from illicit 
manufacture and processing.
The reason for the increase in availability of new 
benzodiazepines in Europe is not entirely clear. In part, 
the increase mirrors the general increased availability of 
a range of NPS since the mid 2000s. In addition, given the 
widespread use of prescription benzodiazepines in society, 
and their diversion to the illicit drug market, the increase 
in new benzodiazepines might also be partially related 
to well-intentioned restrictions in the legal supply of 
authorised benzodiazepine medicines and the introduction 
of prescription limits to prevent or reduce harms among 
patients, such as dependence. While this is speculative, 
some support for this may come from the increasing 
number of fake benzodiazepine medicines that have been 
seized on the illicit drug market in the past few years that 
contain new benzodiazepines.
In the future, it is likely that new benzodiazepines with high 
potency and that are easy to synthesise will continue to 
be introduced into the market. In addition, there might be 
efforts to circumvent the (chemical) definition of generic 
approaches, as has been seen for other NPS.
The ongoing coronavirus disease 2019 (COVID-19) 
pandemic and related response measures may affect the 
existing benzodiazepine drug markets in unpredictable 
ways. Such effects may extend to changes in use and 
patterns of use of benzodiazepines, including a possible 
increase in prescriptions in order to treat insomnia 
and anxiety related to the pandemic. It may also lead 
to temporary shortages due to supply chain issues. 
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Ultimately, such changes may lead to a greater demand for 
new benzodiazepines, such as individuals seeking out new 
benzodiazepines to self-medicate, or inadvertently using 
new benzodiazepines from the use of fake medicines.
This report provides a technical review of the current body 
of knowledge regarding new benzodiazepines that are 
monitored by the EMCDDA. The aims of this report are to 
strengthen situational awareness of new benzodiazepines in 
Europe, and to help stakeholders prepare for and respond to 
public health and social threats caused by such substances.
I Background
I History of the development of benzodiazepines
The first benzodiazepine used as a medicine, 
chlordiazepoxide (1), was the accidental result of 
a research programme to develop new tranquillisers by 
the pharmaceutical company F. Hoffmann-La Roche 
AG in the 1950s. In the course of the research and 
development process, the chemist in charge, Leon 
Sternbach, and his team realised that, instead of the 
benzheptoxdiazines they had intended to synthesise, 
they had made quinazoline 3-oxides (Sternbach et al., 
1979). The structure was subsequently determined as 
a 1,4-benzodiazepine.
Several 2-amino-1,4-benzodiazpine 4-oxides were 
patented in 1959, including chlordiazepoxide. The 
substance became commercially available as a medicine 
in 1960 under the trade name Librium, and it soon 
replaced the more toxic barbiturates to treat anxiety 
and sleep disorders. In 1963, diazepam (Valium) 
followed and it is still one of the most popular and widely 
prescribed benzodiazepines. Since then, a variety of 
structurally modified benzodiazepines have become 
available, with regional differences regarding the range 
of benzodiazepines approved by national medicine 
authorities.
Benzodiazepines are widely prescribed for various 
psychiatric disorders and have become indispensable 
medications in anaesthesiology and emergency care.
(1) 7-Chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine-4-oxide.
I Legitimate uses of benzodiazepines
Benzodiazepines used as medicines are produced by 
licensed pharmaceutical companies and authorised 
and marketed according to national legislation. In 
most countries, benzodiazepines are prescription-only 
medicines and are subject to additional restrictions on 
their supply, use and possession under drug control laws.
Benzodiazepines are used to treat a range of conditions, 
including anxiety, insomnia, epilepsy and muscle spasms, 
and to manage withdrawal symptoms from alcohol. In 
addition, they are also used as premedication prior to 
or during surgical procedures (short-term sedation), 
and for analgosedation (2) in intensive care. The varying 
prescribing patterns of therapeutic application of 
benzodiazepines are caused by the fact that, despite 
qualitatively similar clinical effects, there are important 
quantitative differences in the pharmacodynamic 
spectra and pharmacokinetic properties of different 
benzodiazepines.
Benzodiazepines are recommended for short-term use 
at the lowest possible dose in order to reduce the risks of 
tolerance, dependence and withdrawal symptoms.
I International control measures
In most countries, benzodiazepines authorised as 
medicines are controlled under drug control laws 
and are available by prescription only. This is in 
agreement with the 1971 United Nations Convention on 
Psychotropic Substances, which currently controls 38 
benzodiazepines (3). These are alprazolam, bromazepam, 
brotizolam, camazepam, chlordiazepoxide, clobazam, 
clonazepam, clorazepate, clotiazepam, cloxazolam, 
delorazepam, diazepam, estazolam, ethyl loflazepate, 
etizolam (since 2020), flualprazolam (since 2020), 
fludiazepam, flurazepam, flunitrazepam, halazepam, 
haloxazolam, ketazolam, loprazolam, lorazepam, 
lormetazepam, medazepam, midazolam, nimetazepam, 
nitrazepam, nordazepam, oxazepam, oxazolam, 
phenazepam (since 2016), pinazepam, prazepam, 
temazepam, tetrazepam and triazolam (Figure 1).
(2) Analgosedation is a sedative-minimising technique; although not 
eliminating the use of sedatives entirely, it prioritises pain control and 
analgesia use, saving sedative agents for rescue therapy only.
(3) A total of 37 of them are under Schedule IV (flunitrazepam was 
transferred to Schedule III in 1995).
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I New benzodiazepines in Europe
In the context of this report, ‘new benzodiazepines’ are 
defined as NPS that contain a benzodiazepine core, including 
structurally closely related compounds (e.g. thienodiazepines), 
and that are not controlled under the international drug 
control system. They also include three benzodiazepines – 
phenazepam, etizolam and flualprazolam – that were formerly 
classed as NPS but have recently been controlled under the 
international drug control system.
The term ‘designer benzodiazepine’ has been used 
in analogy to ‘designer drugs’, based on the idea of 
intentionally modifying an established pharmaceutical 
or illicit drug to circumvent national and/or international 
control measures. Other terms used include ‘novel 
benzodiazepines’ (EMCDDA, 2017) or ‘new research 
benzodiazepines’ (Wohlfarth et al., 2017). Most new 
benzodiazepines were described in patent or scientific 
literature before their emergence in the drugs market.
I Emergence of new benzodiazepines
In Europe, the EU Early Warning System, operated by the 
EMCDDA, monitors and responds to the appearance of 
NPS, under the terms of Regulation (EC) No 1920/2006 (as 
amended by Regulation (EU) 2017/2101) (4) (EMCDDA, 
2019a) and Council Framework Decision 2004/757/JHA 
(as amended by Directive (EU) 2017/2103).
As of 28 February 2021, the EMCDDA was monitoring 
30 new benzodiazepines through the EU Early 
Warning System (Figure 2) (EMCDDA, 2020). Despite 
this relatively large number, the market in Europe is 
dominated by a handful of substances. In the past few 
(4) Regulation (EU) 2017/2101 of the European Parliament and of the 
Council of 15 November 2017 amending Regulation (EC) No 1920/2006 as 
regards information exchange on, and an early warning system and risk 
assessment procedure for, new psychoactive substances, OJ L 305, 
21.11.2017, p. 1 (https://eur-lex.europa.eu/legal-content/EN/
TXT/?uri=CELEX:32017R2101).
years, etizolam and flualprazolam, in particular, have 
played an increasingly important role in this market in 
some parts of Europe, especially in the manufacture 
of fake benzodiazepine medicines, such as diazepam 
and alprazolam tablets (EMCDDA, 2019b; EMCDDA, 
2019c; Nielsen and McAuley, 2020). However, this may 
change, as etizolam and flualprazolam were placed under 
international control in November 2020.
New benzodiazepines notified to the EU Early 
Warning System
The first new benzodiazepine to appear on the drugs 
market in Europe was phenazepam in 2007 (EMCDDA, 
2017) (5). It was typically sold as a ‘legal high’ but was 
also deliberately mis-sold as, or used to make, fake 
versions of benzodiazepine medicines in some countries. 
Phenazepam was originally developed as a medicine in 
Russia (then the USSR) in 1975, and continues to be 
marketed as such in Russia and other countries of the 
former Soviet Union. The identification of phenazepam 
on the European drugs market was followed by that of 
etizolam in 2011 (EMCDDA and Europol, 2012). Like 
phenazepam, etizolam is also authorised as a medicine 
in some countries. Between 2008 and 2011, both 
phenazepam and etizolam were subjected to control 
measures in several Scandinavian countries (e.g. 
Sweden, Norway and Finland). Following this, other new, 
unregulated, benzodiazepines started to be sold on the 
‘legal high’ market in Europe.
Pyrazolam (6) was the first ‘designer benzodiazepine’ 
advertised for sale online from mid 2012 on (EMCDDA and 
Europol, 2013; Moosmann et al., 2013a). The compound 
resembles alprazolam, with the phenyl moiety substituted 
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attached to C
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. Flubromazepam (7) and diclazepam (8) 
followed pyrazolam onto the market in 2013. Following 
this, an increasing number of new benzodiazepines 
emerged on the market in Europe, bringing to 30 the total 
number monitored as of 28 February 2021 (Figure 2).
The 30 new benzodiazepines identified so far in Europe are 
listed in Table 1 on page 8, together with information 
on their chemical structure, year of appearance, main 
phase I metabolites and relevant references (Moosmann 
and Auwärter, 2018).
In 2019, the EMCDDA issued risk communications on 
flualprazolam (EMCDDA, 2019b) and etizolam (EMCDDA, 
2019c) to the Early Warning System Network that 
highlighted concerns related to increased availability of 
the substances in Europe, reported harms, and their use to 
make fake tablets of commonly prescribed benzodiazepine 
medicines.
Other possible new benzodiazepines
Although it is unclear why some new benzodiazepines 
have come to dominate the market, and not others, it is 
noteworthy that two of them, phenazepam and etizolam, 
are authorised medicines. It is possible that other 
benzodiazepines authorised as medicines and not under 
international control might emerge as new benzodiazepines 
in the European drug market in the future. These include 
flutazolam, which is structurally related to the controlled 
haloxazolam and is used as a medicine in Japan; 
cinolazepam (available in, for example, Austria, Bulgaria, 
Czechia, Hungary, Slovakia and Romania); doxefazepam (e.g. 
available in Italy); flutoprazepam (e.g. available in Japan); 
gidazepam (available in Russia and Ukraine); metaclazepam 




marketed); mexazolam (available in, for example, Japan 
and Portugal); and quazepam (available in, for example, the 
United States, Japan and Spain).
I Availability, size of the market
The size of the new benzodiazepines market is not known. 
As estimated from the seizures of police and customs 
authorities, new benzodiazepines do not seem to play 
a major role when compared with other NPS groups 
such as synthetic cannabinoids or cathinones (Figure 3). 
In 2019, 1 334 seizures of new benzodiazepines were 
reported to the EU Early Warning System (1 240 (93 %) 
of which were reported by the Member States), reflecting 
around 3.8 % of the total number of seizures of NPS (5.6 % 
in the Member States).
FIGURE 3
Seizures of NPS reported to the EU Early Warning 




















Timeline of benzodiazepines formally notified to the EU Early Warning System for the first time, 2007–2020
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I International legal response to new benzodiazepines
As of February 2021, none of the new benzodiazepines 
monitored by the EMCDDA had been risk assessed at the 
EU level.
In 2015, the Expert Committee on Drug Dependence 
(ECDD) of the World Health Organization (WHO) 
pre-reviewed phenazepam. Following analysis of the 
information provided in the pre-review report, it was 
decided that there was sufficient evidence of dependence 
and harm to proceed directly to a critical review during 
the meeting (WHO, 2016). In 2016, the United Nations 
Commission on Narcotic Drugs (CND) followed the 
recommendation of the ECDD to add phenazepam to the 
list of controlled substances under Schedule IV of the 1971 
United Nations Convention on Psychotropic Substances.
The ECDD reviewed etizolam at its 26th meeting in 1989 
(WHO, 1989) and at its 27th meeting in 1990 (WHO, 
1991). At the 37th ECDD meeting in 2015, the committee 
pre-reviewed etizolam and recommended that a critical 
review was warranted (WHO, 2016). Etizolam was critically 
reviewed at the 39th ECDD meeting in 2017 and was 
recommended to remain under surveillance considering 
the insufficiency of data regarding dependence, abuse and 
risks to public health (WHO, 2018).
In 2019, etizolam (WHO, 2020a) and flualprazolam (WHO, 
2020a) were assessed at the 42nd meeting of the ECDD. 
Subsequently, both etizolam and flualprazolam were 
placed under international control at the 63rd session of 
the CND in 2020, following the recommendation of the 
ECDD to add them to Schedule IV of the 1971 United 
Nations Convention on Psychotropic Substances (UNODC, 
2020; WHO, 2020a). These control measures came into 
effect on 3 November 2020 (UNODC, 2020).
In 2020, clonazolam (WHO, 2020b), diclazepam (WHO, 
2020c) and flubromazolam (WHO, 2020d) were assessed 
at the 43rd meeting of the ECDD and were recommended 
to be included in Schedule IV of the 1971 United Nations 
Convention on Psychotropic Substances.
In Germany, many prescription benzodiazepines are 
controlled by the ‘Betäubungsmittelgesetz’ (BtMG) 
(Narcotics Law) and listed in Annex III to the BtMG 
(marketable or prescribed drugs). Pharmaceutical drug 
preparations containing benzodiazepines up to certain 
maximum levels are usually exempted from the narcotic 
prescription regulation (‘exempted preparations’) and 
can be prescribed on a regular prescription. Specified 
maximum quantities per pharmaceutical form (tablet, 
suppository, ampoule, volume unit for drops) and/or 
maximum quantities per package are also regulated. 
Maximum amounts are defined individually for each 
active substance (e.g. for alprazolam, it is up to 1 mg), and 
result from Annex III to the BtMG. Quantities exceeding 
the stated amounts require a narcotic drug prescription, 
which is associated with increased bureaucratic 
expenditure and is monitored by the corresponding 
national authority, the Federal Institute for Drugs and 
Medical Devices (Bundesinstitut für Arzneimittel und 
Medizinprodukte). Substances controlled by the BtMG 
without such exemptions are camazepam, cloxazolam, 
delorazepam, ethyl loflazepate, etizolam, fludiazepam, 
flunitrazepam, haloxazolam, nimetazepam, phenazepam 
and pinazepam (etizolam and phenazepam were added 
in July 2013). New benzodiazepines such as diclazepam 
and flubromazepam were added to Annex II to the BtMG in 
November 2015.
Benzodiazepines that have recently appeared on the 
German market were not covered by this legislation. In 
response, the annex to the German law on NPS (Neue-
psychoaktive-Stoffe-Gesetz (NpSG)) was extended 
to include several groups of substances, among them 
the group of benzodiazepines generically defined by 
their chemical structure, in July 2019. This includes 
1,4-benzodiazepines, 1,5-benzodiazepines, their triazolo 
and imidazolo derivatives and a number of structural 
subgroups (loprazolam-, ketazolam-, oxazolam- and 
chlordiazepoxide-line compounds). In contrast to the 
BtMG, the NpSG allows criminal prosecution only for 
trafficking drugs; the purchase and possession of drugs 
for self-use are not covered under penal law, although 
seizures of these substances by law enforcement 
are authorised.
Case study of a national response: Germany
13
New benzodiazepines in Europe – a review
I Replacement
It is possible that other new benzodiazepines will replace 
recently controlled benzodiazepines, such as etizolam and 
flualprazolam, on the NPS market. One possibility is the 
re-emergence of flubromazolam and deschloroetizolam, 
which were first notified in Europe in 2014 (EMCDDA 
and Europol, 2015). Data from the Welsh Emerging 
Drugs and Identification of Novel Substances Project 
(Wedinos) appear to suggest that flubromazolam and 
deschloroetizolam have recently re-emerged on the drug 
market in the United Kingdom and are being used to 
make fake diazepam, fake alprazolam, fake temazepam 
and fake zopiclone (Wedinos, 2020). In the United States, 
there has also been a recent increase in detections of 
these substances in forensic cases, including drug-
related deaths (Center for Forensic Science Research and 
Education, 2021).
I Physical, chemical and pharmacological properties
I Physical and chemical description
All compounds classified as ‘benzodiazepines’ have 
a shared core structure and, according to their chemical 











The structural cores of several subgroups of benzodiazepines and indicative Markush structures
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At the time of publishing this report, all new 
benzodiazepines that have appeared on the 
drug market belong to five of the aforementioned 
groups: 1,4-benzodiazepines, 2,3-benzodiazepines, 
thienodiazepines, thienotriazolodiazepines and 
triazolobenzodiazepines.
Physical description
Most of the new benzodiazepines are described as white 
and odourless crystalline powders in their pure form. Less 
pure substances may show yellowish discolouration and 
an unpleasant ‘chemical’ smell due to residual solvents 
and impurities from synthesis. Benzodiazepines are rather 
lipophilic drugs, with very limited solubility in water and 
non-polar aliphatic solvents. Their solubility in aliphatic 
alcohols or more polar solvents, such as chloroform, 
is much greater. For the new benzodizepines, typical 
octanol−water partition coefficients (expressed as log K
OW
 
or log P) at pH 7.4 (log D
7.4
) are between 1 (e.g. pyrazolam) 
and 3.25 (e.g. phenazepam).
Chemical stability
In general, pure and dried benzodiazepines can be regarded 
as chemically stable. However, in solutions, they can be 
unstable, particularly if they contain structural elements 
such as a nitro moiety. The stability of benzodiazepines 
in different solvents and biological matrices, stored at 
temperatures of between 20 °C and –80 °C, has been 
addressed in several studies (Melo et al., 2012; Skopp et al., 
1998; Skopp, 2004). The most unstable compounds were 
shown to be representatives of the nitrobenzodiazepine 
family (Robertson and Drummer, 1998). Pettersson 
Bergstrand et al. (2016) investigated the stability in urine for 
1 month of the following new benzodiazepines: clonazolam, 
deschloroetizolam, diclazepam, etizolam, flubromazepam, 
flubromazolam, flutazolam, meclonazepam, nifoxipam, 
phenazepam and pyrazolam. Flubromazepam and the 
nitrobenzodiazepines clonazolam, meclonazepam and 
nifoxipam were unstable in urine at ambient temperature 
and at – 4 °C. After 4 weeks at – 4 °C, the meclonazepam 
concentration decreased to 8 % of its initial value. Another 
study showed that meclonazepam and 3-methylclonazepam 
were unstable in plasma when stored in glass, but not when 
stored in polypropylene tubes at –20 °C (Coassolo et al., 
1985). Although the data published so far suggest a possible 
instability of any newly emerging nitrobenzodiazepines, 
it is recommended to investigate new compounds for 
their analytical stability. The ideal sample storage should 
be –20 °C or lower prior to analysis and collection tubes 
should be chosen with care (e.g. polypropylene versus glass; 
addition of sodium fluoride or fluoride oxalate).
Methods for identification and analysis
Owing to the extended conjugated π-electron system, the 
chemical identification of benzodiazepines can generally 
be carried out by ultraviolet (UV) spectroscopy, although 
the UV spectra can be very similar for compounds with the 
same chromophore, thereby requiring a chromatographic 
separation for unambiguous identification. Mass 
spectrometric techniques, nuclear magnetic resonance 
spectroscopy and infrared or Raman spectroscopy 
are also suitable for the chemical identification of 
benzodiazepines. For the analysis of biological samples, 
gas chromatography–tandem mass spectrometry 
(GC-MS/MS) and liquid chromatography–tandem 
mass spectrometry (LC-MS/MS) are usually applied. 
Immunoassay screening can also be applied successfully 
(Pettersson Bergstrand et al., 2017), unless the expected 
concentrations are very low, as is the case for extremely 
potent newer benzodiazepines such as flunitrazolam 
(Ameline et al., 2019). However, in the case of a positive 
immunochemical assay, laboratories have to be prepared 
to detect the whole range of new benzodiazepines for 
confirmation. Otherwise, the finding might be incorrectly 
interpreted as a ‘false positive’.
Manufacturing methods and chemical precursors
The synthesis of new benzodiazepines can include 
the introduction of a triazolo ring to precursor 
1,4-benzodiazepines (Kleemann et al., 2009), which are 
readily available as pure substances because of their 
pharmaceutical use. Examples are pyrazolam (from 
bromazepam), clonazolam (from clonazepam) and 
nitrazolam (from nitrazepam). Owing to the generally 
greater potency of the corresponding triazolo derivatives, 
modifications of new benzodiazepines already sold 
on the NPS market have been achieved in this way, 
for example flubromazolam (from flubromazepam), 
flualprazolam (from norfludiazepam, also known as 
norflurazepam) and flunitrazolam (from fonazepam, 
also known as norflunitrazepam). While various other 
routes have been described, a typical synthesis route of 
1,4-benzodiazepines involves the use of halogenated 
2-amino-benzophenone, which is reacted with methyl 
2-aminoacetate under cyclisation.
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I Physical and pharmaceutical form
Prescription benzodiazepines are most commonly 
available as tablets, capsules, solutions for injection/
infusion, oral solutions and suppositories.
New benzodiazepines are marketed as ‘research chemicals’ 
in the form of often highly pure, crystalline powders, 
but also as tablets, capsules or in blotter form. They are 
sometimes available in different strengths that seem to be 
adjusted to the potency of the substance, as is the case 
with medicinal products containing benzodiazepines. A few 
studies have examined the strength of products containing 
new benzodiazepines sold on the NPS market. These 
show that, in at least some cases, the products contained 
the declared amount of the substance (Moosmann et al., 
2013a; Moosmann et al., 2013b); however, large variances 
were reported in other cases, for example 0.59–1.39 mg 
(mean 0.94 mg; n = 13) for diclazepam tablets declared 
to contain 1 mg (Moosmann et al., 2014). In addition, 
new benzodiazepines are increasingly used to make fake 
versions of commonly prescribed medicines such as 
alprazolam and diazepam tablets. The strength of these 
fake products is rarely reported.
I Pharmacology
The GABA system and benzodiazepine receptors
Benzodiazepines mainly act via the GABA receptor family, 
targeting the central GABA
A
 receptor located in post- and 
presynaptic membranes (Mohsin and Qadir, 2015).
GABA
A
 receptors are ligand-gated ion channels built of 
five heteromeric protein subunits, abundantly expressed 
in organisms containing a nervous system (Olsen and 
Sieghart, 2008), with GABA being the endogenous ligand. 
GABA
A
 receptor activation leads to hyperpolarisation 
and inhibition of neurotransmission, thereby, depending 
on the location of the respective receptors in the central 
nervous system, leading to the different pharmacological 
effects seen with benzodiazepines. Sixteen different 
GABA
A 
receptors, comprising seven distinct subunit 
families (α 1–6, β 1–3, γ 1–3, ρ, δ, ε and θ), have been 
described in humans, with the majority consisting 
of two α subunits, two β subunits and one γ subunit. 
The respective isoforms are dispersed within specific 
regions of the nervous system, thereby accounting for 
the various pharmacological effects of benzodiazepines. 
Benzodiazepines do not activate the targeted receptor 
directly, but increase the frequency of GABA-activated 
channel-opening by binding as positive allosteric 
modulators, hence increasing channel conductance 
(Chebib and Johnston, 2000). This mechanism leads 
to increasing efficacy of GABA at the GABA
A
 receptors, 
resulting in the anxiolytic, anticonvulsant, muscle relaxant, 
hypnotic and sedative properties of benzodiazepines. The 
binding site of benzodiazepines is at the interface of an 
α and a γ subunit. Receptors carrying a γ2 subunit are 
more sensitive to benzodiazepines than those equipped 
with a γ1 subunit (Olsen and Sieghart, 2008).
The overall receptor affinity of benzodiazepines is highly 
dependent on the α subunit. For example, some GABA
A
 
receptors containing an α4 or α6 subunit with β and γ2 
do not bind traditional benzodiazepines (Archer and 
Sternbach, 1968). In addition, a receptor carrying an α1 
subunit is said to be linked to the addictive properties 
of benzodiazepines (Tan et al., 2011). Benzodiazepines 
can also interact with a structure known as the peripheral 
benzodiazepine receptor. This translocator protein (TSPO) 
(18 kDa) is the sole target for Ro5-4864 (also known as 
4-chlorodiazepam), a compound that has been shown to 
induce anxiety and convulsions in rats; this compound 
recently became available on the internet drug market, 
and was formally notified in 2016 (EMCDDA, 2017; Pellow 
and File, 1986). Binding affinities of Ro5-4864, however, 
are distinctively different among various species (Gavish 
et al., 1999). Binding to the TSPO can result in anxiolytic 
effects, without the sedative side effects associated 
with benzodiazepines (Rupprecht et al., 2009). However, 
the common pharmacological effects exhibited by 




Information about receptor affinities and subtype 
specificity of new benzodiazepines – if data are available 
at all – is scarce. Thus, it is impossible to predict with 
certainty the pharmacological effects of newly emerging 
substances. There is, however, a high probability that the 
effects on humans are similar to those of therapeutically 
used benzodiazepines, with benzodiazepine antagonist 
flumazenil being capable of reversing those effects. 
A paper published by Sanna et al. (1999) showed that 
the anxiolytic effects of etizolam outweighed its sedative 
properties, which is probably caused by a lower intrinsic 
activity at GABA
A
 receptors containing an α1 subunit.
Pharmacodynamics
In general, new benzodiazepines show the same range 
of effects as benzodiazepines marketed as medicinal 
drugs. These are anxiolytic effects, sedation, muscle 
relaxation, anticonvulsant effects and sleep-inducing 
effects, mediated by binding as allosteric modulators 
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to GABA
A
 receptors (see above). Benzodiazepines can 
also have amnestic and euphoric/mood-lifting effects. 
In terms of pharmacodynamics, the main difference 
between benzodiazepines is their duration of action and 
their relative potency. In general, benzodiazepines can 
be categorised as ‘short-acting’ (duration of action is 
typically in the range of 1–12 hours, e.g. midazolam and 
triazolam), ‘intermediate-acting’ (typically 12–40 hours 
of action, e.g. lorazepam) or ‘long-acting’ (duration of 
action > 40 hours, e.g. diazepam and flubromazepam). 
This usually corresponds to ‘short’ (1–24 hours), ‘medium’ 
(24–48 hours) and ‘long’ (> 48 hours) elimination half-
lives, although, in some cases, the duration of action can 
be long in spite of a relatively short elimination half-life. 
This applies to benzodiazepines that are metabolised 
to pharmacologically active compounds showing longer 
elimination half-lives than the parent compound, for 
example diazepam metabolised to the longer-acting 
nordiazepam. Moreover, potency varies over a large 
scale, with the most potent drugs producing strong 
effects at doses of well below 1 mg (e.g. triazolam 
and flubromazolam), while, for example, oxazepam 
produces similar effects at doses of about 20 mg. 
A further distinction is the onset of action, which can 
vary depending on the absorption rate and the route of 
administration.
In vitro studies
A limited number of in vitro studies are available on 
new benzodiazepines, and data are mostly restricted to 
compounds that were pursued for approval as medicines, 
such as phenazepam and etizolam.
In vitro, phenazepam and its metabolite 
3-hydroxyphenazepam potentiate GABA responses with 
EC
50
 values of 6.1 nM and 10.3 nM respectively, compared 
with the value of 13.5 nM for diazepam (Kopanitsa et al., 
2001, 2002).
In isolated neurons, etizolam behaved as a full 
benzodiazepine receptor agonist, similar to nitrazepam 
and diazepam (Yakushiji et al., 1989).
In 2018, on the basis of published binding values to GABA
A
 
receptors, a quantitative structure–activity relationship 
(QSAR) model to predict GABA
A
 receptor binding was 
suggested (Waters et al., 2018), which might be helpful 
to roughly estimate the binding activity of newly emerging 
compounds.
Animal studies
Animal studies are available for a limited number of new 
benzodiazepines, among them 4′-chlorodiazepam – with 
a focus on potentially neuroprotective properties (Leonelli 
et al., 2005; Mills et al., 2008) – and etizolam (Woolverton 
and Nader, 1995) and phenazepam (Molodavkin et al., 
1996, 2003), which were compared with already well-
characterised benzodiazepines.
In laboratory animals, etizolam induced muscle relaxation, 
reduced conflict behaviour and had anticonvulsive activity 
(Johnson and Funderburk, 1978; Tahara et al., 1978). 
Depending on the parameter and the animal studied, 
etizolam has been reported to be approximately as active, 
and up to six times as active, as diazepam (Fukuda and 
Tsumagari, 1983).
The sedative, tranquillising and muscle relaxant effects 
of flualprazolam in mice were discussed in a patent by 
The Upjohn Company (Hester, 1976). Flualprazolam was 
found to be more potent than alprazolam in all of the tests 
conducted. The central nervous system depressant activity 
of flualprazolam was further explored in a study of a series 
of triazolobenzodiazepine compounds (Hester et al., 
1971). The authors reported that compounds substituted 
with chlorine (i.e. triazolam) or fluorine (i.e. flualprazolam) 
at the ortho-position of the phenyl ring attached to the 
benzodiazepine moiety were found to exhibit dramatically 
enhanced activity, compared with the unsubstituted 
compound (i.e. alprazolam).
Human studies
Human studies are conducted for drug candidates only 
during clinical evaluation, for example etizolam (Bertolino 
et al., 1989; Bramanti et al., 1990; Casacchia et al., 1990; 
De Candia et al., 2009; Fukami et al., 2010; Pariante et 
al., 1989; Savoldi et al., 1990), which was shown to be 
similarly as effective as other benzodiazepines that were 
authorised as medicines at the time, such as alprazolam.
The results of clinical trials showed that etizolam produced 
significant improvements in chronic anxiety, phobic ideas, 
associated depressive symptoms and episodic anxiety, and 
was significantly more effective than placebo (Casacchia 
et al., 1990; Savoldi et al., 1990). In a double-blind study 
among patients with generalised anxiety disorders 
associated with depressive symptoms, the effectiveness 
and tolerability of etizolam and alprazolam were compared. 
The results showed that both drugs had marked anxiolytic 
and antidepressive activity and that there was no 
significant difference between the two drugs in terms of 
overall anxiolytic effectiveness (Pariante et al., 1989).
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Pharmacokinetics
Information on the pharmacokinetics of new 
benzodiazepines is limited. Studies in humans were 
carried out for phenazepam (Zherdev et al., 1982) and 
etizolam (Fracasso et al., 1991).
In humans, etizolam is a short-acting benzodiazepine. In 
a study of single- and multiple-dose pharmacokinetics 
of etizolam in healthy subjects, the maximum plasma 
concentration (C
max
) was reached within 0.5–2 hours in 
all subjects after a single oral administration of 0.5 mg of 
etizolam. The mean elimination half-life averaged 3.4 hours 
(Fracasso et al., 1991).
Metabolism
The metabolism of new benzodiazepines generally does 
not differ from that of ‘traditional’ benzodiazepines. 
Most compounds undergo extensive phase I metabolic 
transformations, mainly mediated by the cytochrome 
P450 (CYP) enzyme family (UNODC, 1997; Xu et al., 
2005). The compounds are predominantly metabolised 
by CYP3A4 enzymes. To a lesser extent, CYP3A5, 
CYP2B6, CYP2C18 and CYP2C19 enzymes are 
also involved in the metabolism of benzodiazepines 
(Fukasawa et al., 2007; Kilicarslan et al., 2001; Mizuno 
et al., 2009). Glucuronidation and acetylation by 
uridine 5′-diphosphoglucuronosyltransferase (UGT) 
and N-acetyltransferase 2 (NAT2), respectively, are 
the major enzymes involved in phase II metabolism of 
benzodiazepines.
Depending on their subclass, the following metabolic 




• 1,4-benzodiazepines: hydroxylation mainly 
occurs at the C-3 position; the minor site is C-4′ 
(Breimer, 1979).
• Imidazo and triazolo compounds: hydroxylation 
will mainly occur at the methyl group of the 
annealed heterocycle or the C-4 position 
(Breimer, 1979; Gorski et al., 1999; Kitagawa et 
al., 1979).
 º Dealkylation.
• 1,4-benzodiazepines carrying an alkyl moiety at 
N-1 are often prone to dealkylation (Schwartz et 
al., 1965).
 º Reduction of the nitro moiety.
• The nitro moiety of 1,4-benzodiazepines (at the 
C-7 position) or triazolobenzodiazepines (at 
the C-8 position) is reduced to the amine group 
(Coller et al., 1999; Mattila and Larni, 1980).
  Phase II.
 º O-Glucuronidation.
• In urine, benzodiazepines carrying a hydroxyl 
moiety (or the hydroxylated metabolites of 
benzodiazepines) are excreted as conjugates 
of glucuronic acid. In the case of, for example, 
lorazepam and oxazepam, glucuronidation can 
be almost complete (Greenblatt, 1981; Hyland et 
al., 2009).
 º N-Glucuronidation.
• The imidazo-benzodiazepine midazolam and 
triazolobenzodiazepines are partly excreted as 
N-glucuronides of the parent compound. In the 
case of midazolam, the conjugation occurs at the 
N-2 position (Hyland et al., 2009).
 º Acetylation.
• The amine function of reduced nitro (triazolo-)
benzodiazepines can be acetylated metabolically.
The metabolites (in vivo and in vitro) observed for the 
benzodiazepines discussed in this review are summarised 
in Table 1 on page 8. Except for adinazolam (Fraser 
et al., 1993; Lahti et al., 1983), etizolam (Fracasso et al., 
1991; Nakamae et al., 2008) and phenazepam (Maskell 
et al., 2012; Zherdev et al., 1982), all data published on 
the metabolism of those compounds result from studies 
performed as a reaction to the compounds emerging on 
the drug market.
There are limited data on the specific enzymes 
involved in the metabolism of new benzodiazepines. 
In a study from 2017, Noble et al. found that CYP3A4 
and CYP3A5 accounted for the formation of the 
flubromazolam metabolites α-hydroxyflubromazolam, 
4-hydroxyflubromazolam and α,4-dihydroxyflubromazolam. 
‘Classical’ triazolo-/imidazobenzodiazepines such 
as alprazolam, triazolam and midazolam are also 
hydroxylated at the α- and 4-positions by enzymes of 
the CYP3A family (Masica et al., 2004). Vikingsson et al. 
(2017) suggested that the reduction of the nitro moiety 
in meclonazepam was catalysed by CYP3A4 and that the 
conjugation leads to 7-acetamidomeclonazepam by NAT2.
Most of the phase I metabolites of benzodiazepines are 
pharmacologically active. Exceptions are found with 
the amino metabolites of nitrobenzodiazepines such as 
the 7-amino metabolites of clonazepam or nitrazepam. 
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Some metabolites are also marketed as pharmaceutical 
products, such as temazepam, nordazepam and 
oxazepam, the main metabolites of diazepam. Some 
metabolites of triazolobenzodiazepines, for example 
the α-OH metabolite in the case of alprazolam and 
triazolam, show high binding affinities towards GABA
A
 
and are considered to be at least as active as the parent 
compound (Hester and Von Voigtlander, 1979). On the 
contrary, 4-OH metabolites generally show a reduced 
biological activity (Baselt, 2011). Significant binding 
affinity at the GABA
A
 receptor was also reported for 
α-OH-midazolam glucuronide, a phase II metabolite of 
midazolam (Bauer et al., 1995).
Interindividual genetic variability in metabolising 
enzymes
Several enzymes involved in the metabolism of 
benzodiazepines are expressed polymorphically. 
Polymorphisms of CYP3A4 and CYP3A5 do not seem 
to affect benzodiazepine metabolism; CYP2C19 
polymorphisms, however, have been reported to have 
significant impact, especially for clobazam, etizolam 
and diazepam (Fukasawa et al., 2005; Goldstein, 2001; 
Parmeggiani et al., 2004). The elimination half-life of 
diazepam in people who are CYP2C19 poor metabolisers 
was twice as long as it was for normal metabolisers 
(Bertilsson et al., 1989). Regarding phase II metabolism, 
polymorphisms have been described for NAT2 
enzymes mediating N-acetylation of benzodiazepines 
carrying an amino function (natively or as the result of 
nitroreduction). Olivera et al. (2007) observed a reduction 
in the metabolism rate for 7-aminoclonazepam, the 
major phase I metabolite of clonazepam. Thus, altered 
metabolism rates due to polymorphisms can increase 
toxicity and lead to different windows of detection 
following drug uptake.
Interactions with other drugs
In general, any CYP-inhibiting or -inducing drug can 
have effects on the metabolisation of benzodiazepines 
by altering the elimination of the drug. This can result in 
clinically significant changes of effect size and alteration 
of the window of detection. CYP3A4 inhibitors such as 
grapefruit juice, the selective serotonin reuptake inhibitor 
fluoxetine, azole antifungal drugs and some antibiotics 
(e.g. erythromycin) drastically reduce benzodiazepine 
metabolism and subsequent elimination, which can result 
in adverse effects. Drug accumulation due to decelerated 
metabolism can influence overall drug toxicity.
The combined uptake of benzodiazepines with alcohol, 
opioids or other central nervous system depressants 
can result in a mutual increase of the respective 
pharmacological effects, such as increased sedation, 
impaired motor coordination and respiratory depression. 
Lethal outcomes after mixed drug consumption have 
been reported repeatedly (Ellefsen et al., 2017; Koch 
et al., 2018; Moody, 2004). Although some studies 
suggest that benzodiazepines and opioids might alter the 
pharmacokinetic effects of one another, this interaction 
may not be clinically significant. It seems much more likely 
that the pharmacodynamic interactions of these drugs are 
responsible for the mutual reinforcement of effects (Jones 
et al., 2012).
Structure–activity relationships and drug design
The structure–activity relationships (SARs) of 
benzodiazepines were first studied by Sternbach et al. 
and Hester et al. in the late 1960s and 1970s (Sternbach 
et al., 1968; Hester and Von Voigtlander, 1979). The 
following SARs are based on their observations for 
1,4-benzodiazepines and triazolobenzodiazepines 
(Figure 5).
  The substituent at C-7 (C-8 for triazolobenzodiazepines) 
is of paramount importance (Sternbach, 1971). The 
activity can be increased by an electron-withdrawing 




). In the case 
of 1,4-benzodiazepines, an increase in activity was 
observed alongside an increase in electronegativity.
  For 1,4-benzodiazepines and triazolobenzodiazepines, 
a halogen atom (F or Cl) bound to the ortho-position of 
the phenyl ring significantly enhances activity.
  Substitution at N-1 has a decisive effect on the activity 
of 1,4-benzodiazepines.
  For triazolobenzodiazepines, a methyl substituent at 
C-1 showed the most significant increase in activity 
(tested H to n-propyl), and bulky substituents, such as 
phenyl groups, led to a loss of activity.
  A decrease in activity has been described for 
1,4-benzodiazepines with an electron donor present at 
C-7 and a substituent in the para-position of the phenyl 
ring. Substitutions at C-6, C-8 and C-9 also lowered the 
activity of the compounds (Sternbach et al., 1968), as 
does a substituent at C-3.
  The phenyl ring at C-5 appeared to be the best option, 
with only pyridyl derivatives showing remarkable activity.
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  According to Waters et al. (2018) substituents on the 
R4′-position of the phenyl ring show a strong steric 
repulsion at the GABA
A
 receptor hence decreasing the 
activity of the compound.
  A considerably lower activity is also observed by 
substitution of the carbonyl function at C-2 by a thione 
(Sternbach et al., 1968).
To predict the biological activity and binding affinity of 
benzodiazepines becoming available on the ‘legal high’ 
market, Waters et al. (2018) used a QSAR approach. 
Based on a learning set of 69 known benzodiazepines, 
the model was applied to predict the binding affinities of 
22 new benzodiazepines by relating biological activity to 
structural descriptors. According to the authors, the critical 
structural elements resulting in high binding affinities were 
the position of two H-bond acceptors, two aromatic rings 
and a hydrophobic group. Benzodiazepines with these 
features showed a greater binding affinity towards the 
GABA
A
 receptor than most prescription benzodiazepines. 
The highest binding affinities (log 1/c) were predicted 
for the three triazolobenzodiazepines flunitrazolam, 
clonazolam and flubromazolam, which is in good 
agreement with the observations made by Hester et al. 
(1971) that triazolobenzodiazepines are more potent than 
the corresponding 1,4-benzodiazepines.
QSAR models and SAR evaluations can be helpful to 
predict the biological activity of new benzodiazepines, but 
should not be regarded as a replacement for in vitro and in 
vivo testing. An overview of the predicted binding affinities 
to GABA
A
 receptor and dosages by Waters et al. (2018) 
can be found in Table 2 on page 20.
I Health and social risks
I Acute toxicity
Animal data
For many benzodiazepines authorised as medicines, 
LD
50
 (median lethal dose) values in various species are 
available. For example, the LD
50
 of orally administered 
etizolam was reported to be 4 300 mg/kg in mice and 
3 550 mg/kg in rats (Tsumagari et al., 1978). The results 
suggest that etizolam is less toxic than diazepam (LD
50
 
values for etizolam were 2–5 times higher than LD
50
 
values for diazepam). In another study, the oral LD
50
 for 
etizolam in mice was reported as 1 780 mg/kg, compared 
with 690 mg/kg for diazepam (Johnson and Funderburk, 
1978). Although lower LD
50
 values were found for other 
benzodiazepines, there is a consensus that the acute 
toxicity of benzodiazepines is relatively low compared 
with that of other drugs of abuse, and can include strong 
sedation, coma, impaired motor function, hypotension and 
respiratory depression in a dose-dependent manner.
FIGURE 5
Structure activity relationship for new benzodiazepines (adapted from Moosmann and Auwärter, 2018)
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TABLE 2
Binding values to the GABA
A
 receptor and dosages of new benzodiazepines









Fonazepam (desmethyl-flunitrazepam) 8.46 1–2
N-Desalkylflurazepam (norflurazepam) 8.44 5–10
3-Hydroxy-phenazepam 8.42 1–2
Diclazepam (Ro5-3448) 8.39 1–2
Flubromazepam 8.37 4–8














(*) Data from https://tripsit.me/ (October 2019).
NB: n.g., not given; n.t., not tested.
Human data
There are numerous reports on benzodiazepine-associated 
fatalities, although monointoxications as the cause of 
death are rare. In most cases, the lethal outcome is 
attributed to multiple drug toxicity, and very often alcohol 
and opioids/opiates are involved.
Some publications and reports suggest that the use of 
new benzodiazepines has become an important issue in 
some countries.
According to the report on drug-related deaths in Scotland 
in 2019 by the National Records of Scotland, ‘street’ 
benzodiazepines (such as etizolam) were implicated in, or 
potentially contributed to, 814 of the 1 264 drug-related 
deaths in 2019 (64 % of all drug-related deaths that 
year). Etizolam has reportedly become the predominant 
benzodiazepine abused in the illicit drug market across 
Scotland. In 2019, etizolam was implicated in, or 
potentially contributed to, the cause of 752 deaths in 
Scotland (compared with 548 in 2018, 299 in 2017 and 
223 in 2016) (National Records of Scotland, 2020).
In a study of 33 post-mortem cases in Sweden and Finland 
that were positive for flualprazolam, the cause of death 
was fatal poisoning by a substance in 23 (70 %) cases, 
and flualprazolam was one of the substances implicated 
in the fatal poisoning in 13 cases (40 %). In two poisoning 
cases, flualprazolam was the only intoxicant reported in 
the cause of death. In these cases, the concentration of 
flualprazolam was 19 and 21 ng/g respectively (Kriikku 
et al., 2020). Flualprazolam was also detected in 197 
blood samples from medicolegal death investigations 
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and driving under the influence of drugs (DUID) cases 
reported between August 2019 and February 2020 in 
the United States (Papsun et al., 2021). A total of 171 
cases were samples collected during medicolegal death 
(i.e. post-mortem) investigations and 22 were DUID 
investigations; four cases were submitted under unknown 
circumstances. In post-mortem cases with quantitative 
results (n = 167), the mean (± standard deviation (SD)) 
flualprazolam concentration was 20 (± 63) ng/ml, the 
median concentration was 8.2 ng/ml, and the range of 
concentrations was 2.0–620 ng/ml. Flualprazolam was 




The available data on genotoxicity and carcinogenicity of 
benzodiazepines and benzodiazepine analogues have 
been reviewed by Brambilla et al. (2007). They collected 
data on 51 drugs, 41 of which are still on the market. They 
were not able to retrieve genotoxicity or carcinogenicity 
data for 12 drugs, but they found at least one test result 
for the remaining 39. Of these, nine tested positive in at 
least one genotoxicity assay, eight tested positive in at 
least one carcinogenicity assay, and five gave a positive 
result in at least one genotoxicity assay and in at least 
one carcinogenicity assay. None of the 11 drugs without 
positive results in these tests showed carcinogenic activity 
in mice and/or rats or in other species. Concerning the 
predictivity of genetic toxicology findings for the result(s) 
of long-term carcinogenesis assays, 18 drugs had both 
genotoxicity and carcinogenicity data; of these, 11 were 
neither genotoxic nor carcinogenic, two were carcinogenic 
in at least one sex of mice or rats but tested negative in 
genotoxicity assays, and five gave a positive response 
in at least one genotoxicity assay and in at least one 
carcinogenicity assay. The authors conclude that only 
a small proportion of the marketed benzodiazepines/
benzodiazepine analogues (8 out of 41) had all the 
data required by current guidelines for the testing of 
pharmaceuticals. No such data are available for new 
benzodiazepines. However, it seems likely that some 
of these compounds share the genotoxic/carcinogenic 
properties of the investigated compounds.
Human data
Some, but not all, benzodiazepines seem to have 
teratogenic effects. Congenital abnormalities, mainly cleft 
lip/palate and anal atresia, were reported to be associated 
with benzodiazepine use during the first 3 months of 
pregnancy (Dolovich et al., 1998; Iqbal et al., 2002). 
Consequently, the US Food and Drug Administration 
(FDA) classified some benzodiazepines (alprazolam, 
chlordiazepoxide, clonazepam, diazepam and lorazepam) 
as category D (i.e. positive evidence of risk exists, 
but benefits from use might outweigh the risk), while 
others were classified as contraindicated in pregnancy 
(estazolam, flurazepam, quazepam, temazepam and 
triazolam). In addition, neonatal withdrawal reactions 
have been described subsequent to pregnant women 
taking benzodiazepine medication during the last weeks 
of pregnancy, and neonatal exposure to benzodiazepines 
during breastfeeding might lead to central nervous system 
depression in infants (Iqbal et al., 2002). There are no 
human data on new benzodiazepines on these issues so 
far, but it can be assumed that some of these compounds 
have teratogenic effects and all of them can produce 
a neonatal withdrawal reaction.
Long-term benzodiazepine use may lead to cognitive 
impairment. Available information from the scientific 
literature suggests that long-term benzodiazepine 
users were significantly impaired, compared with 
controls, in areas such as visuospatial ability, speed of 
processing, memory, concentration and verbal learning 
(Barker et al., 2004). No such data are available for new 
benzodiazepines. However, it seems likely that some of 
these compounds might impair cognitive functions when 
used long term.
Managing poisoning (including mixed intoxications 
with opioids)
Unlike most of the other groups of NPS, new 
benzodiazepines (and opioids) were not included in the 
Novel Psychoactive Treatment: UK Network (NEPTUNE) 
guidelines on the clinical management of acute and 
chronic harms of club drugs and NPS. The main acute 
problems occurring after high doses of opioids or 
benzodiazepines are loss of consciousness and respiratory 
depression. Mono-intoxications with benzodiazepines 
frequently cause unconsciousness, but respiratory 
depression is much less pronounced than with opioids 
and mortality is relatively low (Penninga et al., 2016). For 
both groups of drugs, there are specific antidotes that 
reversibly and competitively block the binding site at the 
receptors, for example flumazenil for benzodiazepines and 
naloxone for opioids. Both antidotes are often used for 
diagnostic reasons in emergency cases with suspected 
benzodiazepine or opioid toxicity (spontaneous reversal of 
the symptoms after application of the antidote is a clear 
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reference to the type of intoxicating agent). However, the 
use of flumazenil in the treatment of patients intoxicated 
with benzodiazepines is controversial because of the 
adverse events (most commonly supraventricular 
arrhythmia and convulsions) associated with this 
treatment, which have been repeatedly reported (Penninga 
et al., 2016), and are potentially caused by conditions 
known to be typical contraindications for flumazenil 
administration (among them co-ingestion of proconvulsive 
drugs, seizure disorder, sedative-hypnotic drug withdrawal 
and intoxicated patients with myoclonic jerking or 
seizure activity). Usually, the clinical management of 
benzodiazepine overdoses can be achieved by mechanical 
ventilation, monitoring and (if needed) stabilisation of 
cardiovascular functions.
I Psychological and behavioural effects
The psychological and behavioural effects of new 
benzodiazepines can be assumed to be similar to 
the known effects of benzodiazepines authorised as 
medicines. ‘Positive’, therapeutically useful effects include 
anxiolysis (Starcevic, 2014), sleep-inducing, amnestic, 
anticonvulsant/muscle-relaxing and mild antidepressant 
effects. On the other hand, particularly among elderly 
patients, muscle relaxation and psychomotoric impairment 
can lead to a greater risk of falling and impaired cognitive 
functioning, and there is some evidence that prolonged 
benzodiazepine use is associated with a greater risk of 
developing dementia (Penninkilampi and Eslick, 2018). 
Although a rather rare complication, ‘paradoxical reactions’ 
after the intake of benzodiazepines have been described 
and can be of concern (Van Der Bijl and Roelofse, 1991). 
These include disinhibition, excitement, convulsions, 
aggressive behaviour and agitated toxic psychosis/
hallucinations. Such unusual reactions seem to occur 
more often among children, young adults and elderly 
people. In addition, there is the well-known potential for 
abuse and the development of dependence (Baldwin et 
al., 2013; Dell’Osso and Lader, 2013), which can lead to 
severe, and even life-threatening, withdrawal symptoms.
I Dependence and abuse potential
Animal data
Drug discrimination studies were performed for many 
classical benzodiazepines. A common finding is that 
benzodiazepines fully substitute for barbiturates or other 
benzodiazepines, and the development of tolerance 
and withdrawal symptoms occurs after repeated 
administration. Although there are no data on new 
benzodiazepines, similar properties can be assumed for 
these compounds.
In a drug discrimination study with rhesus monkeys, 
etizolam, like diazepam, fully substituted for pentobarbital 
(Woolverton and Nader, 1995). The effective dose that 
gave a 50 % response (ED
50
) was 1.2 mg/kg for etizolam 
and 0.8 mg/kg for diazepam.
Human data
Clinical studies with humans also demonstrated that 
these drugs maintain self-administration behaviour 
(Cole, 1990; Griffiths and Weerts, 1997; Woods et 
al., 1987, 1992). However, in comparison to the self-
administration responses produced by highly dependence-
producing drugs such as opioids/opiates or cocaine, 
benzodiazepines are generally regarded as weak 
reinforcers (Jones et al., 2012).
Preclinical evidence exists that benzodiazepines increase 
the rewarding and reinforcing effects of opioids (Panlilio 
et al., 2005; Walker and Ettenberg, 2005), probably by 
amplifying the μ-opioid receptor agonist effects of opioids. 
This might provide an explanation for the widespread co-
use of benzodiazepines among opioid-dependent patients 
(Jones et al., 2012).
Few case reports of etizolam dependence have been 
reported in the scientific literature (Gupta and Garg, 2014; 
Nishii et al.; 2014). The withdrawal symptoms reported 
for etizolam are characteristic of those reported for 
benzodiazepine withdrawal (palpitations, impaired sleep, 
agitation, tremors).
I Effects on the ability to drive and operate machines
Because of the pharmacological effects of benzodiazepines, 
the ability to drive and operate machinery can be massively 
impaired under the acute influence of benzodiazepines, 
depending on the dosage. The main potential problems 
are compromised attention, memory storage and reaction 
times (Stone et al., 2015). The sedative effects also often 
lead to drowsiness and/or dizziness; furthermore, confusion 
and impaired judgement may occur. This is aggravated by 
the co-consumption of alcohol (Downey et al., 2017) or 
other central nervous system depressants. On the other 
hand, the intake of a low dose of a benzodiazepine does not 
necessarily lead to relevant impairment, as recently shown 
for etizolam (up to 1 mg) by Busardo et al. (2019).
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Regarding impairment after continued chronic 
benzodiazepine intake (medication or abuse), tolerance for 
the acutely impairing effects can be assumed. However, 
in this case, fitness to drive and to operate machines 
might be impaired as a result of neurocognitive deficits 
potentially caused by long-term use. The high potency of 
some of the compounds and their varying half-lives can 
lead to unpredictable accumulation and ‘hangover’ effects, 
particularly among users of new benzodiazepines, who 
tend to use relatively large doses.
I Social risks
The social risks connected to the long-term use of 
benzodiazepines in general include, but are not limited 
to, development of lethargy and lack of motivation, 
depression, and dependence (Baldwin et al., 2013; 
Dell’Osso and Lader, 2013). These may negatively affect 
a person’s education, career, family relationships or 
other personal and social relationships, and may result in 
marginalisation.
Along with ethanol, sedative-hypnotic medicines such 
as benzodiazepines are one of the groups of substances 
most commonly used to commit drug facilitated crimes, 
in particular, drug-facilitated sexual assaults and/or are 
identified in biological samples taken from sexual assault 
victims (Xiang et al., 2018). Concerns over the use of 
flunitrazepam (Rohypnol) to commit drug-facilitated sexual 
assault were a major factor in its withdrawal from the 
European market (in this case, the risk outweighed the 
therapeutic benefit).
Between 2019 and the first half of 2020, the EMCDDA 
has received a limited but concerning number of reports 
indicating that new benzodiazepines appear to have been 
used as incapacitating agents in cases of rape and sexual 
assault. The substances mentioned in these reports were 
clozapine, clonazolam, diclazepam, flubromazolam and/
or flualprazolam, all of which are monitored as NPS by the 
EMCDDA. In some cases, liquids containing one or more of 
these substances were seized in connection to the cases. 
Some of these cases appear to have occurred in clusters 
around a particular geographical location. Case reports of 
drug-facilitated crimes involving the apparent use of new 
benzodiazepines have also been reported in the literature 
(Qian et al., 2020; Xiang et al., 2018).
The use of benzodiazepines to commit drug-facilitated 
crimes could cause serious individual and public health 
issues, as well as serious social harms.
I Extent and patterns of use, availability and potential for diffusion
I Prevalence of use
Characteristics of user groups
User groups of new benzodiazepines are not well 
characterised. Based on their effects and their similarities 
to prescription benzodiazepines, it can be assumed that 
new benzodiazepines are used to help with insomnia 
and to reduce stress (‘self-medication’), by people who 
experience benzodiazepine dependence, in polydrug-
use settings to counteract the effects of stimulants 
or hallucinogens, to enhance and prolong the ‘high’ 
of other drugs (usually opioids), and/or to alleviate 
withdrawal effects caused by other dependence-
producing drugs. People using fake medicines containing 
new benzodiazepines will be unaware that they are 
using them. It also appears that there is interest in new 
benzodiazepines by some psychonauts, as is the case with 
other NPS. Benzodiazepines appear to be perceived by 
users as relatively safe and socially acceptable (Peters et 
al., 2007).
Use by vulnerable groups
Benzodiazepines are frequently used by people who 
use opioids, including high-risk opioid users (EMCDDA, 
2018). In some cases, new benzodiazepines have 
become a relatively low-cost alternative to prescription 
benzodiazepines available on the illicit market. The misuse 
of benzodiazepines contributes to increased morbidity and 
mortality among high-risk opioid users.
New benzodiazepines might also be considered appealing 
by prisoners (Ford and Berg, 2018), although the available 
data suggest that synthetic cannabinoids are more 
popular in this environment. A study of French male 
prisoners found that 37 % were chronic benzodiazepine 
misusers and that many high-risk opioid users switched 
from illicit opioids to benzodiazepines when incarcerated, 
either to make their incarceration bearable or to cope with 
withdrawal symptoms (Expertise Collective, 2012).
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I Patterns of use
When used as a ‘standby medication’ by users of 
stimulants or hallucinogens, the frequency of uptake can be 
estimated to be rather low. However, when used for other 
purposes, such as ‘self-medication’ of insomnia or stress 
reduction, more regular use seems likely. In polydrug-use 
settings including opioid users, frequent and excessive use 
of benzodiazepines is very common to enhance or prolong 
the effects of other drugs or to avoid withdrawal symptoms.
Route of administration
Most prescription benzodiazepines are administered orally 
or intravenously. Less common routes of administration 
are intramuscular injection and rectal administration. For 
new benzodiazepines, oral administration seems to be the 
most common route of administration, although injecting, 
smoking/vaping and snorting have also been reported.
Dosage
‘Typical’ doses for new benzodiazepines vary over a wide 
range and depend on factors such as binding affinity to the 
GABA
A
 receptor, protein binding and their ability to cross 
the blood–brain barrier (El Balkhi et al., 2020). Since most 
of the compounds sold on the ‘legal high’ market have 
never undergone pharmacological studies and clinical 
trials, the ‘common’ doses are estimated and discussed on 
internet platforms such as TripSit (https://tripsit.me/). For 
the benzodiazepines discussed in this report, the dosage 
information, according to TripSit, can be found in Table 2 
on page 20, with individual doses ranging from as low 
as 0.08 mg for flunitrazolam to 30 mg for adinazolam.
I Availability, supply and involvement of organised crime
Production
The available information suggests that most new 
benzodiazepines, like many other NPS, are synthesised 
in chemical and pharmaceutical laboratories in China; 
they are shipped as bulk powders to Europe. Once in 
Europe, the powders are processed into finished products; 
typically, these are tablets, but capsules, blotters and 
e-liquids for vaping have also been reported. Some of 
the new benzodiazepines, particularly etizolam, may be 
sourced from companies in India, typically as finished 
medicinal products (Figure 6).
Police Scotland reported that large-scale illicit 
manufacturing of benzodiazepine tablets, predominantly 
containing etizolam, occurred between 2017 and 2018 
in Scotland and that crime groups are increasingly 
becoming involved in the production of these tablets. The 
huge demand for the tablets on the illicit drug market has 
resulted in several large-scale producers setting up illicit 
production sites in the west of Scotland. The detection 
of these production sites illustrates that professional 
equipment (such as multi-station rotary pill presses; 
Figure 7) is being used by illicit manufacturers to enable 
quick and efficient large-scale production. During 2017, 
police seized 1.67 million tablets containing etizolam at 
FIGURE 6
Tablets containing etizolam that originated from India, 
seized by Spanish customs in February 2019
Photo: Spanish customs.
FIGURE 7
Rotary pill press seized at an illicit production site
Photo: Police Scotland.
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one such production site. Their estimated street value 
was EUR 1.9 million. The etizolam was sourced as a bulk 
powder from China, diluted, mixed with blue dye and then 
pressed into tablets using an industrial tablet press. The 
amount of etizolam in each tablet was around 0.8 mg, 
meaning that the amount of active ingredient needed 
to produce the number of tablets seized at the time 
of the police raid was less than 1.5 kg (EMCDDA and 
Europol, 2019).
Trafficking
There are indications that benzodiazepines are ordered 
from legitimate chemical and pharmaceutical companies 
in China, which ship the products typically as powders by 
mail and courier services to retailers and individuals in 
Europe. As with other NPS, in some cases consignments 
containing new benzodiazepines are misdeclared as other 
goods or concealed using methods similar to those used 
for established drugs. Furthermore, finished products 
might be ordered from unlicensed online pharmacies 
based in India.
Distribution among users, so called ‘social supply’, also 
seems to play an important role, in particular for opioid and 
poly-drug users.
Internet markets
New benzodiazepines may be sold on the surface web 
and the darknet (EMCDDA and Europol, 2017). There are 
a variety of internet retailers offering ‘research chemicals’ 
and ‘legal highs’ containing new benzodiazepines.
Falsified (fake) medicines
Initially, many new benzodiazepines were sold under 
their own names and advertised as ‘research chemicals’ 
and ‘legal highs’. While this continues to be the case, 
increasingly these substances are also being used to 
produce fake benzodiazepine medicines, particularly fake 
diazepam tablets (Valium) and fake alprazolam tablets 
(Xanax), which are then sold on the illicit drug market. In 
some cases, the fake tablets are packaged in blister packs 
resembling those of the legitimate products (Figure 8).
In the past few years, etizolam and flualprazolam, in 
particular, have played an increasingly important role in 
the new benzodiazepine market in some parts of Europe, 
especially in making fake diazepam and alprazolam tablets 
(EMCDDA, 2019b, 2019c; Nielsen and McAuley, 2020). 
European drug-checking services Wedinos, in Wales, 
United Kingdom, (9) and Saferparty, Zurich, Switzerland, (10) 
have reported an increasing number of fake Xanax and 
Valium tablets containing flualprazolam, flubromazolam, 
etizolam and other new benzodiazepines in recent years.
In Scotland, criminal groups are known to be involved in 
the large-scale illicit manufacture and distribution of fake 
benzodiazepine medicines. Typically made to look like 
10-mg diazepam tablets, and known as ‘street Valium’, 
these fakes often contain new benzodiazepines. During 
2016 and 2017, one such benzodiazepine, etizolam, was 
reported to have become the predominant substance 
within the illicit market for benzodiazepines, with 65 % of 
tablets found containing the substance (EMCDDA and 
Europol, 2019).
Data from Wedinos, the drug-testing service operated by 
Public Health Wales in the United Kingdom, suggest that 
flubromazolam and deschloroetizolam have recently re-
emerged on the drug market in the United Kingdom and 
are being used to make fake diazepam, fake alprazolam, 
fake temazepam and fake zopiclone (Wedinos, 2020). 
Some recent poisonings in the United Kingdom have been 
linked to flubromazolam sold as fake benzodiazepine 
medicines (Public Health England, 2020).
(9) Wedinos is a drug-testing service in the United Kingdom operated by 
Public Health Wales (http://www.wedinos.org/about_us.html).
(10) Saferparty is a drug-testing service in Zurich, Switzerland (https://www.
saferparty.ch/ueber-uns.html).
FIGURE 8
Fake diazepam tablets packaged in blister packs 
resembling those of the legitimate products. The tablets 
were purchased as ‘Diazepam Activis’ but were found to 
contain flubromazolam and diazepam on analysis by 
Wedinos in May 2020
Photo: Wedinos.
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In a case from Singapore and Malaysia, Erimin 5 tablets 
contained phenazepam instead of nimetazepam (Lim et 
al., 2017).
Quality on the market
Typical impurities
Typical impurities have not been analytically assessed 
so far. It can be assumed that such contaminants would 
typically originate from synthesis (by-products that were 
not sufficiently separated during clean-up of the raw 
material), depending on the chosen route of synthesis.
Contaminants
So far, no typical contaminants have been analytically 
detected.
New benzodiazepines as adulterants
A recently published study reported an outbreak of 
adulteration of illicit opioids with new benzodiazepines in 
Vancouver, Canada, between October 2018 and January 
2020 (Laing et al., 2021). The reasons for this type of 
adulteration are unclear; however, it has been suggested 
that benzodiazepines may serve to ‘heighten’ or prolong 
the ‘high’ associated with opioid use, may help users to 
cope with opioid withdrawal symptoms or may control the 
‘descent phase’ of opioid intoxication.
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I Conclusion
New benzodiazepines have established themselves 
as a group of NPS. It is likely that new substances 
belonging to this group will continue to appear, not only 
to satisfy customers such as ‘psychonauts’ seeking new 
drug experiences, but also to circumvent drug tests 
(e.g. workplace drug testing) and as an alternative to 
unavailable prescription medicines.
Over the past few years, there has been an increase in 
the number and availability of new benzodiazepines on 
the drug market in Europe and, increasingly, elsewhere. 
As of 28 February 2021, the EMCDDA, through the EU 
Early Warning System on NPS, is monitoring 30 new 
benzodiazepines that have appeared on the drug market 
since the mid 2000s. Of these, more than 80 % were 
detected for the first time between 2014 and 2020. 
Despite this relatively large number, the market in Europe 
is dominated by a handful of substances. In the past 
few years, etizolam and flualprazolam, in particular, 
have played an increasingly important role in the new 
benzodiazepine market in some parts of Europe, especially 
in making fake diazepam and alprazolam tablets.
Overall, these developments give rise to concerns about 
both individual and public health for a number of reasons. 
The pharmacology and toxicology of new benzodiazepines 
is largely unknown, and the risks associated with their 
use may be higher than those associated with the use of 
authorised benzodiazepine medicines. In addition, the very 
nature of unregulated markets means that these risks may 
be amplified because users cannot be certain of the dose 
used. In some cases, users may not be aware that they are 
using these substances; therefore, they might be at higher 
risk of severe poisoning, particularly if taken in combination 
with other central nervous system depressant drugs, such 
as alcohol and opioids. Of particular concern is the growing 
use of new benzodiazepines to make falsified (fake) tablets 
of commonly prescribed benzodiazepine medicines, such 
as diazepam (Valium) and alprazolam (Xanax), and the 
involvement of criminal groups in producing such tablets. In 
some cases, the fake tablets are packaged in blister packs 
resembling those of the legitimate products, which makes 
it more difficult for consumers to spot the fakes. Serious 
adverse events, such as severe poisoning, involving such 
fake medicines have been reported in Europe. Other risks 
might be related to the potential presence of adulterants, 
other substances or synthesis by-products from illicit 
manufacture and processing.
The reason for the increase in availability of new 
benzodiazepines in Europe is not entirely clear. In part, 
the increase mirrors the general increased availability of 
a range of NPS since the mid 2000s. In addition, given the 
widespread use of prescription benzodiazepines in society, 
and their diversion to the illicit drug market, the increase 
in new benzodiazepines might also be partially related 
to well-intentioned restrictions in the legal supply of 
authorised benzodiazepine medicines and the introduction 
of prescription limits in order to prevent or reduce harms 
among patients, such as dependence. While this is 
speculative, some support for this may come from the 
increasing number of fake benzodiazepine medicines that 
have been seized on the illicit drug market in the past few 
years that contain new benzodiazepines.
In future, it can be expected that compounds with 
high potency and that are easy to synthesise will 
continue to be introduced into the market. Therefore, 
further triazolo derivatives can be expected as newly 
emerging candidates. In addition, there might be efforts 
to circumvent the (chemical) definition of generic 
approaches, as has been seen for other NPS.
The ongoing COVID-19 pandemic and related response 
measures may affect the existing benzodiazepine drug 
markets in unpredictable ways. Such effects may extend 
to changes in use and patterns of use of benzodiazepines, 
including a possible increase in prescriptions in order 
to treat insomnia and anxiety related to the pandemic. 
Ultimately, such changes may lead to a greater demand 
for new benzodiazepines, such as individuals seeking out 
new benzodiazepines to self-medicate, or inadvertently 
using new benzodiazepines through the use of fake 
medicines. New benzodiazepines may also be mis-sold 
as, or used to adulterate, other illicit drugs – such as the 
recent phenomenon of ‘benzo dope’ in Canada, where new 
benzodiazepines have been used to adulterate the illicit 
opioids supply.
Given the growing complexity of the market in new 
benzodiazepines and its strong links with the broader 
illicit drug market, particularly the large demand for 
benzodiazepine medicines such as alprazolam and 
diazepam, there is a need to ensure that we continue to 
strengthen the ability to detect, assess and respond to 
existing and new threats in a timely and effective way, 
to prevent or reduce the public health and social harms 
caused by this group of substances.
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I Annex – Profiles of selected new benzodiazepines
I Flualprazolam
Background information
Flualprazolam can be regarded as the 2′-fluoro derivative 
of alprazolam or an analogue of flubromazolam (exchange 
of the bromine atom by a chlorine atom), and was first 
mentioned in a patent filed in 1969 by The Upjohn 
Company under the name 8-chloro-1-methyl-6-(o-
fluorophenyl)-4H-s-triazolo[4,3-a][1,4]-benzodiazepine. 
In this patent, the synthesis of various triazolo-1,4-
benzodiazepines by reaction of 1,4-benzodiazepine-
2-thione precursors with acetic acid hydrazide was 
described. Although the patent was finally granted in 1976 
(Hester, 1976), flualprazolam has never been marketed by 
The Upjohn Company.
Its first appearance on the market for NPS dates back 
to 2017.
Physical and chemical description
Flualprazolam is a white powder in its pure form.
IUPAC name: 8-Chloro-6-(2-fluorophenyl)-1-methyl-
4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine.









Monoisotopic mass: 326.0735 u; [M+H]+: 327.0807 u.
Melting point: 203–204 °C (Hester, 1976).
Predicted log D
7.4
 (using ACD/Labs Percepta Platform – 
PhysChem Module): 2.44 (http://www.chemspider.com/
Chemical-Structure.8534493.html).
Pharmacology
Owing to the structural similarity with the 
triazolobenzodiazepines alprazolam and triazolam, it can be 
expected that the potency of flualprazolam is comparable 
(a dose equivalent to 10 mg of diazepam is about 0.5 mg 
for alprazolam and triazolam) and that it is rapidly absorbed 
after oral ingestion. Considering the pattern of halogen 
substitution, the elimination half-life of flualprazolam is likely 
to be in a range similar to that of triazolam (approximately 
2 hours) or alprazolam (6–12 hours).
In the patent by Hester (Hester, 1976), the following ED
50
 
values, in mg/kg, are given for flualprazolam for mice 
after intraperitoneal administration: 0.056 (chimney 
test: ability of mice to back up and out of a vertical glass 
cylinder within 30 seconds), 0.016 (dish test: mice remain 
in a Petri dish for more than 3 minutes), 0.028 (pedestal 
test: mice stay in a pedestal for more than 1 minute), 0.009 
(nicotine antagonism test: protection from overstimulation 
and death of mice after injection of 2 mg/kg of nicotine 
salicylate prior to flualprazolam administration).
On TripSit (http://drugs.tripsit.me/flualprazolam, accessed 
October 2019), the following data are given, which probably 
originate from non-controlled self-experiments and have to 
be considered with caution: a common oral dose is given 
as 0.25–0.5 mg (light dose, 0.125–0.25 mg; strong dose, 
0.5–1 mg; heavy dose, 1–2 mg). Onset of action is stated 
to occur 10–30 minutes after ingestion, duration of action 
is 6–14 hours and after-effects last 1–36 hours.
Toxicology
There are no data available on the acute or chronic toxicity 
of flualprazolam, but because of the structural similarities 
to well-characterised triazolobenzodiazepines such as 
triazolam, toxicity can be anticipated to be similarly low.
Mei et al. (2019) published a validated LC-MS/MS 
method for the detection and quantification of 13 new 
benzodiazepines, including flualprazolam, in blood samples.
Wagmann et al. (2020) published a study on the 
metabolism of flualprazolam. Seven flualprazolam 
metabolites were tentatively identified. Several CYP and 
UGT isozymes, amongst them CYP3A4 and UGT1A4, were 
shown to be involved in flualprazolam biotransformation 
reactions. Alpha-hydroxy flualprazolam glucuronide, 
4-hydroxy flualprazolam glucuronide and the parent 
glucuronide were identified as the most abundant signals 
in urine, far more abundant than the parent compound 
flualprazolam.
Kriikku et al. (2020) reported the quantitative confirmation 
of flualprazolam in 33 post-mortem cases in Sweden and 
Finland. From this study, the median concentration of 
flualprazolam in blood was 18.0 ng/g (ranging from 3.0 to 
68 ng/g); 13 cases listed flualprazolam as a cause of death.
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Papsun et al. (2021) reported that flualprazolam was 
detected in 197 blood samples from medicolegal death 
investigations and human performance cases reported 
between August 2019 and February 2020 in the United 
States. A total of 171 cases were samples collected during 
medicolegal death (i.e. post-mortem) investigations and 22 
were from human performance (i.e. DUID) investigations; 
four cases were submitted under unknown circumstances. 
In post-mortem cases with quantitative results (n = 167), the 
mean (± SD) flualprazolam concentration was 20 (± 63) ng/
ml, the median concentration was 8.2 ng/ml, and the range 
of concentrations was 2.0–620 ng/ml. Four remaining 
post-mortem cases were reported to have tested positive 
for flualprazolam, however, flualprazolam has not been 
quantified in those cases (< 2.0 ng/ml). In drug-impaired 
driving cases (n = 22), the mean (± SD) flualprazolam 
concentration was 22 (± 18) ng/ml, the median 
concentration was 14 ng/ml and the range of concentrations 
was 4.4–68 ng/ml. Flualprazolam was commonly (83 % of 
the time) found in combination with opioids (e.g. fentanyl).
Dependence and abuse potential
There are no data available on the dependence and abuse 
potential of flualprazolam. However, it can be assumed 
that the abuse liability and the potential to produce 
dependence are similar to those of other chemically related 
triazolobenzodiazepines such as alprazolam or triazolam.
Epidemiology
There are no data on the use of flualprazolam in the 
general population.
In general, benzodiazepines play a major role in DUID 
offences, and flualprazolam has recently been reported 
in a few DUID cases, which mainly occurred in the United 
States (UNODC, 2019). A case in which flualprazolam was 
used in an anaesthesia robbery case in China in November 
2017 has also been reported (Qian et al., 2020).
I Flubromazolam
Background information
Flubromazolam can be regarded as the triazolo derivative 
of the new benzodiazepine flubromazepam; it was one of 
the first new benzodiazepines entering the market in 2014, 
and, from its chemical structure, it is closely related to 
flualprazolam and triazolam. It is covered by a patent held 
by The Upjohn Company and granted in 1972, but specific 
data on this compound were not included.
The first appearance of flubromazolam as a new 
benzodiazepine offered in online shops dates back to 
2014. Flubromazolam has been detected in fake Xanax 
(alprazolam) tablets (EMCDDA, 2020). According to 
another report (Pope et al., 2018), candy-like pills found 
on an intoxicated patient participating in a methadone 
programme contained flubromazolam (0.18 mg) next to 
a much higher dose of clonazolam (16 mg). A urine sample 
of the patient was found to be positive for flubromazolam 
and its metabolites (Pope et al., 2018).
Andersson and Kjellgren (2017) recently evaluated 
discussions on a Swedish online forum (https://www.
flashback.org/) regarding flubromazolam and concluded 
that this new benzodiazepine is generally described 
as very potent and long-lasting. It was rated as highly 
addictive and can lead to many, possibly severe, side 
effects such as memory loss and loss of control.
Physical and chemical description












Monoisotopic mass: 370.0229 u; [M+H]+: 371.0302 u
Melting point: 213–214 °C (patent US 20100130481, 
compound [0075] (Cook et al., 2010)); 205.3 °C (swgdrug 





 (using ACD/Labs Percepta Platform – 
PhysChem Module): 2.50 (http://www.chemspider.com/
Chemical-Structure.10684757.html).
Experimentally determined log D
7.4
: 2.40 (Manchester et 
al., 2018).
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Pharmacology
Owing to the structural similarity to the 
triazolobenzodiazepines alprazolam and triazolam, 
flubromazolam can be expected to be similarly potent (a 
dose equivalent to 10 mg of diazepam is about 0.5 mg for 
both alprazolam and triazolam) and to be rapidly absorbed 
after oral ingestion, although data from a self-experiment 
suggest that resorption can be delayed, for example 
because of food intake (Huppertz et al., 2018). Considering 
the pattern of halogen substitution, the elimination half-life 
of flubromazolam is likely to be in a range similar to that 
of the half-life of triazolam (approximately 2 hours) or the 
half-life of alprazolam (6–12 hours). Data from Huppertz 
et al. (2018) suggest that its half-life is approximately 
10–20 hours. Although these data would be comparable 
to a short or medium duration of action, there were reports 
on long-lasting effects, in particular after ingestion of 
higher doses (Huppertz et al., 2018, Łukasik-Głębocka et 
al., 2016).
Manchester et al. (2018) experimentally determined the 
mean plasma protein binding (89.5 %) and pK
a
 (2.07) 
of flubromazolam. The in-silico predicted binding value 
(log 1/c) was 8.77 (Waters et al., 2018).
Noble et al. (2017) assessed plasma protein binding to be 
89 %, by using an equilibrium dialysis assay, and found 
a hepatic clearance of 0.42 ml/minute/kg, which was 
between the values for diazepam (0.11 ml/minute/kg) and 
alprazolam (0.74 ml/minute/kg).
On TripSit (http://drugs.tripsit.me/flualprazolam, accessed 
October 2019) the following data are given, which 
probably originate from non-controlled self-experiments 
and have to be considered with caution: a common oral 
dose is given as 0.2–0.4 mg (threshold dose, 0.08 mg; 
light dose, 0.1–0.2 mg; strong dose, 0.4–0.6 mg). Onset 
of action is stated to occur 20–45 minutes after ingestion, 
duration of action is 6–12 hours and after-effects last 
6–24 hours. A dose of about 0.25 mg of flubromazolam is 
stated to be equivalent to 10 mg of diazepam.
Toxicology
No data are available on the acute or chronic toxicity of 
flubromazolam, but, owing to the structural similarities 
to well-characterised triazolobenzodiazepines such as 
triazolam, toxicity can be anticipated to be similarly low.
Høiseth et al. (2016) detected flubromazolam in 25 out 
of 77 authentic forensic blood samples; the median 
concentration was 12 ng/ml (range 0.48–100 ng/ml). 
In one case with no other drugs detected, the male, 
a 19-year-old driver, was found to be considerably 
impaired at a blood concentration of 100 ng/ml.
Łukasik-Głębocka et al. (2016) reported on an intoxication 
associated with coma, respiratory depression and 
hypotension after the intake of a self-stated dose of 3 mg 
of flubromazolam. The patient improved after 4 days of 
treatment in hospital. Flumazenil (1.0 mg) temporarily 
improved the patient’s vigilance for about 30 minutes. The 
reported flubromazolam serum concentration in a sample 
taken approximately 19 hours after drug intake was 43 ng/
ml (Łukasik-Głębocka et al., 2016).
Huppertz et al. (2018) reported on a self-experiment 
comprising the ingestion of 0.5 mg of flubromazolam. The 
volunteer noticed muscle-relaxing effects and onset of 
a light tiredness approximately 90 minutes post ingestion. 
He seemed visibly impaired and experienced strong 
sedative effects and repeatedly fell asleep in the time 
interval from 3–10 hours after drug intake. In addition, 
partial amnesia extending beyond 24 hours was reported 
(Huppertz et al., 2018). Peak serum concentrations were 
about 8 ng/ml.
In 2019, Mei et al. published a validated LC-MS/MS 
method for the detection and quantification of 13 new 
benzodiazepines, including flubromazolam, in blood 
samples.
Several publications are dedicated to the metabolism 
of flubromazolam. Huppertz et al. (2015) described the 
formation of a monohydroxylated and a dihydroxylated 
metabolite after incubation with pooled human liver 
microsomes (pHLM). In addition, Pettersson Bergstrand et 
al. (2018) detected the glucuronides of flubromazolam and 
its monohydroxylated metabolites in the urine samples 
of patients. Wohlfarth et al. (2017) identified a total of 
seven metabolites by analysing authentic urine samples 
including two different glucuronides of flubromazolam, an 
N- and an O-glucuronide. Considering data from a self-
administration study (oral, 0.5 mg of flubromazolam), 
Huppertz et al. (2018) suggested targeting the parent 
compound and the monohydroxylated metabolites in urine 
after enzymatic glucuronide hydrolysis, and showed that 
flubromazolam can be detected in hair after a low, single 
oral dose. Noble et al. (2017) showed that hydroxylation 
at the 4- and/or the α-position is catalysed mainly by 
CYP3A4 and (to a somewhat lower extent) CYP3A5, and 
confirmed the metabolite findings of the other groups.
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Dependence and abuse potential
No data are available on the dependence and abuse 
potential of flubromazolam. However, it can be assumed 
that the abuse liability and the potential to produce 
dependence is similar to those of other chemically related 
triazolobenzodiazepines such as alprazolam or triazolam.
Epidemiology
Flubromazolam seems to be one of the most prevalent 
new benzodiazepines. It was frequently detected in a case 
series of patients with admitted or suspected intake of 
NPS presenting to hospitals in Sweden, covered as part of 
the STRIDA project (Bäckberg et al., 2019). More precisely, 
between 2012 and 2016, new benzodiazepine ingestion 
was analytically confirmed in 217 patients; in 42 % (n = 92) 
of these cases, flubromazolam was detected. Most of 
these cases occurred in 2015 (ranging from the end of 
2014 to the beginning of 2016).
Carpenter et al. (2019) reported on ‘designer 
benzodiazepine’ exposures recorded in the United 
States between 2014 and 2017. Of 234 reported single-
agent exposures to new benzodiazepines, 13 were 
flubromazolam cases (5.5 %). Two cases (3 %) were 
reported in 2016 and 11 cases (10 %) in 2017. In the 
majority of these cases (69 %), the effect duration was 
between 8 and 24 hours. The effects were minor or 
moderate in all cases.
In general, benzodiazepines play a major role in DUID 
offences, and flubromazolam has recently been reported 
to occur frequently in DUID cases involving new 
benzodiazepines (in 11 out of a total of 32 cases), which 
mainly occurred in the United States (UNODC, 2019).
I Fluclotizolam
Background information
Fluclotizolam is a thienotriazolodiazepine that first 
appeared in 2017 as a new benzodiazepine and is 
structurally closely related to etizolam. It is thought to be 
about two to three times more potent than etizolam (a 
dose of 10 mg of diazepam is equivalent to about 1 mg of 
etizolam) and to have a somewhat shorter half-life.
Physical and chemical description












Monoisotopic mass: 332.0299 u; [M+H]+: 333.0371 u.
Predicted log D
7.4 
(using ACD/Labs Percepta Platform – 
PhysChem Module): 2.09 (http://www.chemspider.com/
Chemical-Structure.15332007.html).
Pharmacology
To date, no data have been published in the scientific 
literature on the pharmacological properties of 
fluclotizolam. On TripSit (http://drugs.tripsit.me/
fluclotizolam, accessed October 2019), the following data 
are given, which probably originate from non-controlled 
self-experiments and have to be considered with caution: 
a common oral dose is given as 0.25–0.5 mg (light 
dose, 0.25 mg; strong dose, 0.5–0.75 mg; heavy dose, 
≥ 0.75 mg). Onset of action is stated to occur 10–
30 minutes after ingestion, duration of action 3–6 hours 
and after-effects last for 1–14 hours.
Toxicology
No data are available on the acute or chronic toxicity of 
fluclotizolam, but owing to the structural similarities to 
the well-characterised thienotriazolodiazepine etizolam, 
toxicity can be anticipated to be similarly low.
Furthermore, no data have been published on the 
metabolism of fluclotizolam. However, it can be anticipated 
that hydroxylation catalysed by CYP enzymes occurs.
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Dependence and abuse potential
No data are available on the dependence and abuse 
potential of fluclotizolam. However, it can be assumed 
that the abuse liability and the potential to produce 
dependence are similar to those of other chemically 
related thienotriazolodiazepines, such as etizolam.
Epidemiology
There are no available data on the epidemiology of 
fluclotizolam. Although included in the screening method 
since 2018 (about 500 samples analysed per year), at 
the time of writing it had not yet been detected in the 




Diclazepam, also known as Ro5-3448, is the 2-chloro 
derivative of diazepam and was first described by 
Sternbach et al. (1962). Its first appearance as a new 
benzodiazepine dates back to 2013. It seems to be several 
times more potent than diazepam.
Physical and chemical description














Monoisotopic mass: 318.0327 u; [M+H]+: 319.0399 u.
Predicted log D
7.4 
(using ACD/Labs Percepta Platform – 
PhysChem Module): 3.25 (http://www.chemspider.com/
Chemical-Structure.68652.html).
Experimentally determined log D
7.4
: 2.73 (Manchester et 
al., 2018).
Pharmacology
Babbini et al. (1979) showed that diclazepam is 
approximately four to eight times more potent than 
diazepam in terms of reducing motor activity and conflict 
behaviour in rats. Studies by Sternbach et al. (1968) 
found diclazepam to be equally as potent as diazepam 
with regard to muscle relaxant and sedative effects in 
mice and twice as potent than diazepam in cats. The K
i
 
value at recombinant wild-type α1ß2γ2 GABA
A
 receptors 
reflects a binding affinity that is 30 times higher than 
that of diazepam (Sigel et al., 1998). However, Bradley 
and Nicholson (1984) tested the behavioural activity of 
monkeys under diclazepam and diazepam (same dose) 
and did not see differences in the effects.
Manchester et al. (2018) experimentally determined the 
mean plasma protein binding (93.8 %) and the pK
a
 value 
(2.31) of diclazepam. The in-silico predicted binding value 
(log 1/c) was 8.39 (Waters et al., 2018).
On TripSit (http://drugs.tripsit.me/diclazepam, accessed 
October 2019), the following data are given, which 
probably originate from non-controlled self-experiments 
and have to be considered with caution: a common 
oral dose is given as 1–2 mg (light dose, 0.25–1 mg; 
strong dose, ≥ 2 mg). Onset of action is stated to occur 
15–90 minutes after ingestion, duration of action lasts 
8–12 hours and after-effects last 1–24 hours. A dose 
of about 1 mg of diclazepam is stated to be equivalent 
to 10 mg of diazepam (considering the available data, 
potency tends to be somewhat overestimated here).
Toxicology
No data are available on the acute or chronic toxicity of 
diclazepam, but owing to the structural similarities to the 
well-characterised 1,4-benzodiazepines delorazepam, 
lorazepam and lormetazepam, which are metabolites of 
diclazepam, toxicity can be anticipated to be similarly low.
Moosmann et al. (2014) investigated the metabolism 
of diclazepam and performed a self-experiment of oral 
ingestion of 1 mg of the compound. The maximum 
serum concentration was 3.4 ng/ml and the subject did 
not notice any pharmacological effect. They reported 
an elimination half-life of approximately 42 hours. The 
pharmacologically active metabolites lorazepam and 
lormetazepam have shorter elimination half-lives (12 and 
13 hours respectively) and delorazepam has a half-life of 
about 78 hours.
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In 2019, Mei et al. published a validated LC-MS/MS 
method for the detection and quantification of 13 new 
benzodiazepines, including diclazepam, in blood samples.
Høiseth et al. (2016) detected diclazepam in 15 out of 
77 authentic forensic blood samples, and the median 
concentration was 13 ng/ml (range 2.1–57 ng/ml). In one 
case with no other drugs detected, the male, an 18-year-
old driver, was found to be considerably impaired at 
a blood concentration of 57 ng/ml.
Dependence and abuse potential
No data are available on the dependence and abuse 
potential of diclazepam. However, it can be assumed 
that the abuse liability and the potential to produce 
dependence are similar to those of other chemically 
related 1,4-benzodiazepines, such as diazepam.
Epidemiology
Diclazepam was analytically confirmed in four cases of 
a case series of consecutive patients with admitted or 
suspected intake of NPS presenting to hospitals in Sweden 
between 2012 and 2016, as part of the STRIDA project 
(Bäckberg et al., 2019) (1.8 % of all cases with the detection 
of at least one new benzodiazepine, of which most occurred 
between the end of 2014 and the beginning of 2015).
Carpenter et al. (2019) reported on ‘designer 
benzodiazepine’ exposures recorded in the United States 
between 2014 and 2017. Of 234 reported single-agent 
exposures to new benzodiazepines, four were diclazepam 
cases (1.7 %). One case was reported in 2016 and three 
cases (2.7 %) in 2017.
In general, benzodiazepines play a major role in DUID 
offences, and diclazepam has recently been reported 
in one case of a DUID case series involving new 
benzodiazepines (total number: 32 cases), which mainly 
occurred in the United States (UNODC, 2019).
I Clonazolam/clonitrazolam
Background information
Clonazolam was first described in an article written by 
Hester et al. in 1971; it was described as the most active 
compound in the investigated series of 16 6-phenyl-
4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine derivatives, 
being effective in many tests at doses of less than 10 μg/
kg (Hester et al., 1971). The first appearance of clonazolam 
as a new benzodiazepine available via internet shops was 
in 2014.
Physical and chemical description














Monoisotopic mass: 353.0680 u; [M+H]+: 354.0752 u.
Melting point: 229–231 °C (Hester et al., 1971).
Predicted log D
7.4 
(using ACD/Labs Percepta Platform – 
PhysChem Module): 2.24 (http://www.chemspider.com/
Chemical-Structure.15468596.html).
Pharmacology
Hester et al. (1971) described clonazolam as the most 
potent compound of a series of chemically similar 
benzodiazepines.
The in-silico predicted binding value (log 1/c) was given 
as 8.86, which was the second highest value after 
flunitrazolam (8.86), confirming the extremely high potency 
of this compound (Waters et al., 2018).
On TripSit (http://drugs.tripsit.me/clonazolam, accessed 
October 2019), the following data are given, which 
probably originate from non-controlled self-experiments 
and have to be considered with caution: a common oral 
dose is given as 0.2–0.4 mg (threshold dose, 0.05–
0.075 mg; light dose, 0.075–0.2 mg; heavy dose, 0.5–
1 mg). Onset of action is stated to occur 10–30 minutes 
after ingestion, duration of action is 6–10 hours and after-
effects last 1–12 hours.
Toxicology
No data are available on the acute or chronic toxicity of 
clonazolam, but, owing to the structural similarities to 
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the well-characterised triazolobenzodiazepine triazolam 
and the nitrobenzodiazepine clonazepam, toxicity 
can be anticipated to be similar to these established 
benzodiazepines.
In 2019, Mei et al. published a validated LC-MS/MS 
method for the detection and quantification of 13 new 
benzodiazepines, including clonazolam, in blood samples.
Høiseth et al. (2016) detected clonazolam in 7 out 
of 77 authentic forensic blood samples; the median 
concentration was 5.3 ng/ml (range 1.9–11 ng/ml).
Data on the in vitro metabolism of clonazolam after 
incubation with pHLM were published by Huppertz et al. 
(2015); they reported a monohydroxylated metabolite 
and a reduction of the amino function leading to 
8-aminoclonazolam. Meyer et al. (2016) reported a total 
of seven metabolites in human urine samples with 
8-aminoclonazolam, 8-acetamidoclonazolam and one 
monohydroxylated metabolite (probably α-position) 
being the main phase I metabolites, followed by another 
monohydroxylated metabolite (4-position) and three 
glucuronides. The parent compound was detected in all 
authentic urine samples (n = 4), although in relatively 
low concentrations. El Balkhi et al. (2017) confirmed the 
results of Huppertz et al. (2015) after pHLM incubation and 
tentatively identified a further metabolite corresponding to 
a demethylation.
Dependence and abuse potential
No data are available on the dependence and abuse 
potential of clonazolam. However, it can be assumed 
that the abuse liability and the potential to produce 
dependence are similar to those of other chemically 
related and highly potent triazolobenzodiazepines, such as 
triazolam.
Epidemiology
Clonazolam was analytically confirmed in 16 cases of 
a case series of consecutive patients with admitted 
or suspected intake of NPS presenting to hospitals in 
Sweden between 2012 and 2016, as part of the STRIDA 
project (Bäckberg et al., 2019) (7.4 % of all cases with 
the detection of at least one new benzodiazepine). These 
cases mainly occurred in 2015.
Carpenter et al. (2019) reported on ‘designer 
benzodiazepine’ exposures recorded in the United States 
between 2014 and 2017. Of 234 reported single-agent 
exposures to new benzodiazepines, 50 were clonazolam 
cases (21 %). Fourteen cases (21 %) were reported in 
2016 and 36 cases (32 %) in 2017. In the majority of 
these cases (46 %), the effect duration was between 8 and 
24 hours. The effects were minor or moderate in all cases 
but two, which showed ‘major effects’.
In general, benzodiazepines play a major role in DUID 
offences, and clonazolam has recently been reported to 
have occurred in DUID cases (5 out of 32 cases testing 
positive for at least one new benzodiazepine), which 
mainly occurred in the United States (UNODC, 2019).
I N-Desalkylflurazepam (norflurazepam)
Background information
N-Desalkylflurazepam was first mentioned in a patent 
granted to Hoffmann-La Roche Inc. in 1976. It is a long-
acting 1,4-benzodiazepine and is known as the main 
metabolite of flurazepam. It also occurs as a metabolite 
of some other benzodiazepines (e.g. fludiazepem, 
flutoprazepam and quazepam) and was shown to be an 
impurity present in midazolam medicines (Vogt et al., 
2013). It first appeared as a new benzodiazepine available 
online in 2016.
Physical and chemical description












Monoisotopic mass: 288.0466 u; [M+H]+: 289.0538 u.
Melting point: 205–207 °C (Chase, 1976)
Predicted log D
7.4
 (using ACD/Labs Percepta Platform – 
PhysChem Module): 2.80 (http://www.chemspider.com/
Chemical-Structure.4381.html).
Experimentally determined log D
7.4
: 2.82 (Manchester et 
al., 2018).
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Pharmacology
Manchester et al. (2018) experimentally determined the 
mean plasma protein binding (95.5 %), pK
a
 (2.51) and log 
D
7.4
 (2.82) of N-desalkylflurazepam. The in-silico predicted 
binding value (log 1/c) was 8.44 (Waters et al., 2018).
On TripSit (http://drugs.tripsit.me/norflurazepam, 
accessed October 2019) the following data are given, 
which probably originate from non-controlled self-
experiments and have to be considered with caution: 
a common oral dose is given as 5–10 mg (light dose, 
2–5 mg; strong dose, 10–20 mg or more). Onset of action 
is stated to occur 45–120 minutes after ingestion, duration 
of action is 10–16 hours and after-effects last 1–12 hours.
Toxicology
No specific data are available on the acute or chronic toxicity 
of N-desalkylflurazepam. However, N-desalkylflurazepam is 
the main metabolite of flurazepam and accumulates after 
continued flurazepam medication. Therefore, toxicity can be 
anticipated to be similarly as low as for flurazepam.
The LD
50
 in mice after oral administration was determined 
to be 2 250 mg/kg (Garattini et al., 1973). The 
elimination half-life of N-desalkylflurazepam was given as 
74 hours ± 24 hours by Schulz et al. (2012), but the original 
literature was not cited. Greenblatt et al. (1983) reported an 
elimination half-life of 40–200 hours, which could potentially 
lead to extensive accumulation after repeated intake.
Moosmann et al. (2019) detected two hydroxylated 
(hydroxylation was hypothesised to occur at carbon 
atoms 3 and 4′) and one dihydroxylated metabolites of 
norflurazepam after incubation with pHLM.
Dependence and abuse potential
No data are available on the dependence and abuse 
potential of N-desalkylflurazepam. However, it can 
be assumed that the abuse liability and the potential 
to produce dependence are similar to those of other 
chemically related benzodiazepines, such as flurazepam.
Epidemiology
No data are available on the epidemiology of 
N-desalkylflurazepam. Assessing the prevalence of 
N-desalkylflurazepam is complicated by the fact that it 
occurs as an accumulating metabolite of several other 
benzodiazepines.
Carpenter et al. (2019) reported on ‘designer 
benzodiazepine’ exposures recorded in the United States 
between 2014 and 2017. Of a total of 234 reported single-
agent exposures to new benzodiazepines, only one case 




Bromazolam is the bromo analogue of alprazolam and 
was first described by Hester and Von Voigtlander in 1979 
(Hester and Von Voigtlander, 1979). Its first appearance as 
a new benzodiazepine dates back to 2016.
Physical and chemical description












Monoisotopic mass: 352.0324 u; [M+H]+: 353.0396 u.




 (using ACD/Labs Percepta Platform – 
PhysChem Module): 1.86 (http://www.chemspider.com/
Chemical-Structure.19871738.html).
Pharmacology
Bromazolam was investigated pharmacologically by 
Clayton et al. (2015) under the name XLi268 and showed 
K
i




On TripSit (http://drugs.tripsit.me/bromazolam, accessed 
October 2019), the following data are given, which 
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probably originate from non-controlled self-experiments 
and have to be considered with caution: a common oral 
dose is given as 1–3 mg (light dose, 0.5–1 mg; strong 
dose, 3–5 mg or more). Onset of action is stated to occur 
15–45 minutes after ingestion, duration of action is 
5–8 hours and after-effects last 1–12 hours.
Toxicology
No specific data are available on the acute or chronic 
toxicity of bromazolam, but, owing to the structural 
similarity to the well-characterised triazolobenzodiazepine 
alprazolam, toxicity can be anticipated to be similarly low.
Dependence and abuse potential
No data are available on the dependence and abuse 
potential of bromazolam. However, it can be assumed 
that the abuse liability and the potential to produce 
dependence are similar those of to other chemically 
related benzodiazepines, such as alprazolam.
Epidemiology
No data are available on the epidemiology of bromazolam.
GETTING IN TOUCH WITH THE EU
In person
All over the European Union there are hundreds of Europe Direct 
information centres. You can find the address of the centre near-
est you at: http://europa.eu/contact
On the phone or by e-mail
Europe Direct is a service that answers your questions about the 
European Union. You can contact this service 
•  by freephone: 00 800 6 7 8 9 10 11  
(certain operators may charge for these calls) 
•  at the following standard number: +32 22999696 or
•  by electronic mail via: http://europa.eu/contact
FINDING INFORMATION ABOUT THE EU
Online
Information about the European Union in all the official languages 
of the EU is available on the Europa website at: http://europa.eu  
EU publications
You can download or order free and priced EU publications from 
EU Bookshop at: http://bookshop.europa.eu.  
Multiple copies of free publications may be obtained by contact-
ing Europe Direct or your local information centre  
(see http://europa.eu/contact)
EU law and related documents
For access to legal information from the EU, including all EU law 
since 1951 in all the official language versions, go to EUR-Lex at: 
http://eur-lex.europa.eu
Open data from the EU
The EU Open Data Portal (http://data.europa.eu/euodp/en/data)  
provides access to datasets from the EU. Data can be download-
ed and reused for free, both for commercial and  
non-commercial purposes.
About this publication
This report provides a technical review of the current 
body of knowledge regarding new benzodiazepines that 
are monitored by the EU Early Warning System. 
The aims of this report are to strengthen situational 
awareness of new benzodiazepines in Europe, and 
to help stakeholders prepare for and respond to public 
health and social threats caused by such substances.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For 25 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
